cba-usa.org

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

创新，创业，创机遇，迎接全球生物制药新时代

The 23rd Annual Conference

Chinese Biopharmaceutical Association

The Bridge of US-China Biopharmaceuticals

中美生物医药的桥梁



Saturday, June 9th, 2018

One MedImmune Way, Gaithersburg, Maryland 20878

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

MEDIMMUNE MAP

cba-usa.org



1	Auditorium	主会场
2	Multipurpose Room	分会场
3	Vendors	赞助商
4	Café	餐厅
5	Registration	注册
6	Restrooms	洗手间
7	Interview Rooms	面试间
8	Press Room	新闻发布会
9	Atrium	中庭
10	Entrance	入口
11	VIP Sponsor Lounge	休息室

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA WELCOME



A Letter from the CBA President

Dear CBA Members and Friends:

I am greatly honored to welcome all of you to the 23rd Chinese Biopharmaceutical Association in the USA (CBA-USA) Annual Conference. CBA hosts this conference on June 9, 2018 with support from MedImmiune, a member of the AstraZeneca group, which provides the state-of-the-art conference facility on its beautiful campus.

It has been more than two decades of robust growth for the CBA. Twenty-three years ago, we were a tiny group of young scientists working in the USA with ties to China, but we had a big vision: create a platform for collaboration in life sciences and the biopharmaceutical industry. Thanks to the dedication of our members, CBA has grown into a truly global organization with a strong and growing reputation. This conference will serve to reinforce and expand CBA's commitment to fostering greater global collaboration and new partnerships between China and the USA in the biotech and pharmaceutical arenas.

It has been my honor to serve as the chair of the 23rd Annual Conference Organizing Committee. The theme of this year's conference is "Bridging Innovations, Entrepreneurs, and Opportunities to Advance Global Biopharmaceutical Development." We are very fortunate and honored to have more than 25 distinguished leaders speak at our conference. Our program includes keynote speeches of CBA Brilliant Achievement Award recipients and seven sessions that bring together elite minds from around the world to share their insights on the latest progress in global biopharmaceutical development.

CBA has received very generous support this year from our sponsors, which include biopharmaceutical companies, contract research organizations (CROs), biotech service providers, and medical device companies operating in China, the USA, and Canada, as well as the Department of Commence of Maryland. On behalf of CBA, I would like to sincerely thank all of our sponsors for their strong commitment and contributions to the success of this conference.

As the chair of this year's Conference Organizing Committee, I would like to express my profound gratitude to all the committee members and the many CBA members who have worked so diligently to organize every detail to ensure that each of you will greatly enjoy this year's event. I am enormously grateful for your commitment and dedication to this year's conference.

Sincerely,

==========
Frank Li Li, M.D., Ph.D.
President-Elect, CBA-USA
Chair, the 23rd CBA Annual Conference Organizing Committee

cba-usa.org

CBA History and Accomplishments 1995 – 2018

The Chinese Biopharmaceutical Association-USA (CBA-USA) (www.cba-usa.org) is one of the largest Chinese American professional associations in the US. CBA was founded in 1995 by a group of Chinese American biopharmaceutical professionals as a non-political and non-profit organization headquartered in the Washington DC area. The mission of CBA is to promote communication and collaboration among biopharmaceutical professionals and to foster business collaborations among different countries and regions, especially between the US and China.
CBA has an excellent reputation both in China and the US for developing and enhancing friendship and cooperation in the biopharmaceutical and life sciences industries. Our efforts have been applauded by industry executives and prominent leaders from both the US and China. The former China Minister of Health, Dr. Zhu Chen, former US Deputy Secretary of Labor, Samuel Tingsing Mok, former Chinese Ambassadors to the US, Wenzhong Zhou and Daoyu Li, and dozens of prominent leaders from academia, industry and government have attended and addressed at CBA's events. A number of prestigious scientific journals, including Nature, Science, and Bioprocess International, have reported on the CBA, its event, as well as its members.

Since its establishment, CBA has stayed true to its mission in bridging the biopharmaceutical industry between the US and China. Its signature event, the CBA annual conference, which has been successfully held in the US or in China for 22 years, has served as an effective platform that brought together the elite scientific minds, successful entrepreneurs, and government agencies in the pharmaceutical and biotechnology areas. Some of the key topics at the past CBA annual conferences included:

- Cutting edge sciences and technologies in the development of medicines
- Commercialization and globalization of biopharmaceutical development through partnerships
- Regulatory perspectives of pharmaceutical development

In addition to the annual conferences, CBA has hosted and co-hosted with American and Chinese professionals and industrial organizations in biopharmaceutical areas) a large number of workshops and seminars focusing on local and international hot topics, and cutting edge research and technology discoveries. The most recent events include:

- The 9th Human Vaccine Industry Summit 2017, Qingdao, China
- Shanghai BioPharm Forum 2017, Shanghai, China
- Precision Medicine and Immuno-Oncology China 2017, Shanghai, China
- Asia Pharma R&D Summit 2017, Shanghai, China

创新，创业，创机遇，迎接全球生物制药新时代
Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development
CBA - INTRODUCTION

In the past 23 years, CBA has also served as an incubator for talents and entrepreneurs, and a place for professional networking and development. Many former CBA presidents and board members are now established industry leaders in the US and China, such as Dr. Guoliang Yu, Chairman of CrownBio, Dr. Dajun Yang, Chairman and CEO of Ascentage, Dr. Dan Zhang, Chairman of Fountain Medical Development, Dr. Patrick Lu, Chairman and CEO of Sirnaomics, Dr. Dong Xie, Chairman and COO of Frontier Biotechnologies, Dr. Yingxian Xiao, CEO of Shanghai Furen Medicine, Dr. Sujuan Ba, President and COO of National Foundation for Cancer Research, and biotech entrepreneur stars such as Dr. Ping Chen and Dr. Ziping Wei.

Since 2016, CBA has started to organize bimonthly workshops to provide opportunities for sharing expertise and discussing latest topics by experts. CBA also helps members with their career development in the biopharmaceutical industry. Each of these events attracted hundreds of medical, clinical and pharmaceutical students and professionals who were seeking new or advanced career opportunities.

In 2018, CBA launched new initiatives to form multiple small study groups to discuss innovative trends in the biopharmaceutical industry. These are venues for members to share expertise and deepen their knowledge. The Biomarker and Diagnostics Study Group, composed of 19 CBA active members, kicked off the series of activities on May 06, 2018. Other study groups covering other latest trends in drug development are in progress.

CBA is also a place where Chinese American pharmaceutical professionals celebrate. Over the years, the CBA Chinese New Year Gala and summer picnics provided relaxing and fun opportunities for CBA members to connect and celebrate. CBA just celebrated its 23rd anniversary at its 2018 Chinese New Year Gala. The success of the organization is attributed to the active involvement of members around the US who strongly believe in its mission. Today, the global biopharmaceutical and healthcare industry continues to evolve and grow, particularly in China and the Asia Pacific area. The CBA members are ready to rise to the challenges ahead.

Through the persistent efforts of the CBA's strong leadership, its devoted members and volunteers, its sponsors and supporters in the past 23 years, CBA has become a well-recognized Chinese American professional organization with more than 8000 members in the US, China, and the rest of the world.

CBA Sponsors & Donations, please mail to:
P. O. Box 61362
Potomac, MD 20859-1362

CBA Membership Registration:

cba-usa.org

TABLE OF CONTENTS

创新，创业，创机遇，迎接全球生物制药新时代
Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA - PRESIDENTS

FRANK LI LI, M.D., PH.D.
President Elect of Chinese Biopharmaceutical Association (CBA)

Dr. Frank Li Li is the President-Elect of Chinese Biopharmaceutical association (CBA) and a member of board of directors. Dr. Li is currently a Director of Regulatory Affairs at BioVentures in AstraZeneca. He has more than 10 years of experience in Regulatory Affairs of drug development. It includes strategic and tactic planning and execution of IND/CTA and NDA/BLA/MAA in world markets. Dr. Li obtained his PhD degree in Molecular Medicine from Kyoto University, School of Medicine, Japan. He did medical residency in surgical departments after he graduated from a Medical School in China followed by clinical research training for his Master Degree in China-Japan Friendship Hospital and Peking Union Medical College in Beijing, China.

DONG SHEN, M.D., PH.D.
President of Chinese Biopharmaceutical Association (CBA)

Dr. Dong Shen is the President of Chinese Biopharmaceutical association (CBA) and the Chair of CBA board of directors. Dr. Shen graduated with Ph.D. degree from Johns Hopkins University School of Medicine and M.D. degree from Shanghai Jiao Tong University School of Medicine. In the past, Dr. Shen led TCGA breast cancer, lung cancer, ovary cancer and AML projects. All his manuscripts been published at top peer reviewed journals, such as New England Journal of medicine, Nature, Science, Cell, JAMA, Nature genetics, etc. The total number of his citations is over 13,000. Currently Dr. Dong Shen is head of computational and biomarker in lung and prostate disease at Janssen Pharmaceutical companies of Johnson and Johnson.

XU-RONG JIANG, M.D., PH.D.
Immediate Past President Biopharmaceutical Association (CBA)

Dr. Xu-Rong Jiang was the President and Chairman of the Board of Directors in the Chinese Biopharmaceutical Association-USA from 2016-2017. Dr. Xu-Rong Jiang is currently a Quality and Technical Director of AstraZeneca BioVentures. He has served as the Head of Quality for Centus Biotherapeutics Ltd, a joint venture between AstraZeneca and Fujifilm Kyowa Kirin Biologics, as well as the Head of Quality for Archigen Biotech Ltd, a joint venture between AstraZeneca and Samsung Biologics. He was an Associate Director in Analytical Sciences at MedImmune, where he led the Biological Assay Development Group for analytical method development for therapeutic antibodies IND filing, GMP testing, technology transfer and process development, and BLA. He was also a CMC Team Leader for a product from pre-clinical to IND and Phase 1/2 clinical stage of development. Prior to MedImmune, Dr. Jiang was a Principal Scientist in Process & Analytical Sciences at Amgen where he was responsible for development, qualification, validation of potency assays for biologics development. Prior to Amgen, Dr. Jiang was a Senior Scientist at Geron Corporation focusing on gene and cell therapy, high throughput screening, and regenerative medicine with embryonic stem cells. Dr. Jiang received his Ph.D. degree in molecular cell biology from University of London and M.D. in hematology from China Medical University.

创新，创业，创机遇，迎接全球生物制药新时代

cba-usa.org

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CONFERENCE AGENDA - MORNING SESSION

TIME Session (Focused on Immune-Oncology)

7:30-8:30
Registration and Continental Breakfast;
Exhibition Booth Setup

8:30-8:35
Welcome to CBA 23rd Annual Conference
Dong Shen, *M.D., Ph.D., President of CBA*

8:35-8:50
Opening Remarks
1. Mr. Luis Borunda, *Deputy Secretary of the State of MD*
2. Mrs. Xueyuan Xu, *Minister, Embassy of the People's Republic of China in the United States of America*
3. AZ/MEDI-TBD

8:50-8:55
Introduction of CBA Brilliant Achievement Awardee:
Lieping Chen, *M.D., Ph.D.*
Frank Li Li, *M.D., Ph.D., President-Elect of CBA*

8:55-9:20
CBA Brilliant Achievement Award Presentation:
Immunological Principles of Anti-PD-1/PD-L1 Cancer Therapy
Lieping Chen, *M.D., Ph.D., Professor, School of Medicine, Yale University*

9:20-9:25
Introduction of CBA Brilliant Achievement Awardee:
Richard Pazdur, *MD*
Dong Shen, *M.D., Ph.D., President of CBA*

9:25-9:50
CBA Brilliant Achievement Award Presentation 1971-2018:
Personal Reflections on Nixon's War on Cancer
Richard Pazdur, *M.D., Director, Oncology Center of Excellence, FDA, USA*

9:50-10:00
Coffee Break

10:00-10:05
Introduction of CBA Brilliant Achievement Awardee:
Yong-Jun Liu, *M.D., Ph.D.*
Xu-Rong Jiang, *M.D., Ph.D., Immediate Past President of CBA*

10:05-10:30
CBA Brilliant Achievement Award Presentation:
Follow the Science and Capture the Opportunity
Yong-Jun Liu, *M.D., Ph.D., Head of Research, Global R&D, Sanofi*

TIME Session (Focused on Immune-Oncology)

10:30-10:35
Introduction of CBA Brilliant Achievement Awardee:
Laurence J.N. Cooper, M.D., Ph.D.
Sujuan Ba, *Ph.D., Former President of CBA, President and COO of the National Foundation for Cancer Research (NFCR)*

10:35-11:00
CBA Brilliant Achievement Award Presentation:
The Genetic Engineering of T cells: From Bench, to Bedside, to Boardroom
Laurence JN Cooper, *M.D., Ph.D., CEO, ZIOPHARM Oncology*

11:00-11:15
Panel Discussion
Moderator: Sujuan Ba, Ph.D.

11:15-11:35
Special Presentation by WuXi AppTec:
Creating a Pharmaceutical Innovation Ecosystem
Xin Zhang, *Ph.D., Vice President & Global Head of DMPK, Bioanalysis & Abgent, WuXi AppTec*

11:35-12:35
Global Drug Development: ICH and Role of China
Co-Chairs: Jingyu (Julia) Luan, *Ph.D., CDER, FDA, USA*
Xinyu Weng, *Ph.D., CNDA, China*

11:35-12:00
Issues in Multiregional Clinical Trials
Aloka Chakravarty, *Ph.D., Acting Director Office of Biostatistics, CDER, FDA, USA*

12:00-12:25
CNDA's Regulatory Reform: Opportunities and Challenges
Gang Wang, *Ph.D., Former Chief Scientist, CDE, CFDA, China*

12:25-12:35
Panel Discussion
Dan Zhang, *MD, MPH, Chairman, Fountain Medical Development*
Bill Wang, *Ph.D., Executive Director, Clinical Safety Statistics, Merck & Co*
Shoubai Chao, *Ph.D., Chief Operating Officer, CanSino Biologics*

12:35-1:30
Lunch

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CONFERENCE AGENDA - AFTERNOON SESSION



TIME Parallel Sessions A

1:30-2:30
Entrepreneur Incubators and Collaboration - Auditorium
Chair: Huihua (Helen) Mao, *Ph.D., MBA, Co-founder and Senior Vice President, CanSino Biologics*

1:30-1:45
Incubators in Montgomery County, Maryland
Biotech and Montgomery County's Economy
Lily Qi, *Assistant Chief Administrative Officer, Montgomery Co. Office of the Counyt Executive, MD*
Supporting Entrepreneurs in a Sustainable Local Economy
Sarah Miller, *Vice President & Chief of Staff, Montgomery County Economic Development Corporation*

1:45-2:05
Incubators in China
Incubating Future Innovators & Entrepreneurs in Life Science
Zhe Zhi, Vice General Manager, China Resources Life Science Park Co.
Video: Introduction to Tianjin Economic-Technological Development Area (TEDA)

2:05-2:15
Maryland Resources for Business Growth
Felicia Pullam, *Regional Manager, East Asia & Investment Team Lead, Office of International Investment & Trade, MD Dept. of Commerce*

2:15-2:25
Introduction of Maryland International Incubator
Alex Wang, *Ph.D., Director, Maryland International Incubator, University of Maryland (College Park), MD, USA*

2:25-2:30
Panel Discussion

TIME Parallel Sessions B

1:30-2:30
Advanced Translational Medicine - SCBA - Multi-Purpose Room
Co-Chairs: Mitchell Ho, *Ph.D.*
Wanjun Chen, *Ph.D.*

1:30-1:50
CAR-T Cells Targeting Glypicans in Cancer
Mitchell Ho, *PhD, Senior Investigator, Laboratory of Molecular Biology, NCI, NIH*

1:50-2:10
Gut Microbiome Controls Liver Tumor Growth via Bile Acid-Regulated NKT Cells
Chi Ma, *PhD, Staff Scientist, Thoracic & Gastrointestinal Oncology, NCI, NIH*

2:10-2:30
T Regulatory Cells for Immunotherapy to Autoimmunity & Cancer
Wanjun Chen, Ph.D., Senior Investigator, Chief, *Mucosal Immunology Section, NIDCR, NIH*

2:30-3:30
Artificial Intelligence and Big Data in Biopharmaceutical Development - Auditorium
Chair: Chuanhua (Julia) Xing, *Ph.D., Vice President of CBA, Founder, XPrecision and ShiHua Big Data Healthcare*

2:30-2:50
Application of Deep Learning in Drug Discovery
Qingsong Zhu, *Ph.D., Chief Operating Officer, InSilico Medicine*

2:50-3:10
Burn the Haystack: Finding the Needle in Clinical Notes & Genomics at Scale
Nathan Salmon, *Chief Architect, MetiStream*

3:10-3:30
Deep Learning Convolutional Neural Networks Techniques & Their Applications in Biomedical Sciences - A Successful Example in Lung Imaging
ShihChung Lo, *Ph.D., Georgetown Univ. Medical Center & VA Tech.*

2:30-3:30
Real World Evidence Medicine in Biopharmaceutical Development - Multi-Purpose Room
Chair: Yifan, Zhai, *M.D., Ph.D., Chief Medical Officer, Ascentage Pharma*

2:30-2:50
Information Exchange and Data Transformation (INFORMED)
Sean Khozin, M.D., MPH, Associate Director (Acting), OCE, FDA

2:50-3:10
Realizing the Potential of Real World Data and Evidence
Iksha Herr, *MS, PMP, RWE Data & Analytics Leader, AstraZeneca*

3:10-3:30
Panel Discussion
Panelist
Xia Wang, *PhD., Director, Health Informatics, AstraZeneca*

cba-usa.org

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CONFERENCE AGENDA - AFTERNOON SESSION

3:30-3:40

Break

3:40-5:00

Entrepreneurs and Investors

Co-Chairs: Dazhi Lai, *Ph.D., Vice President, CBA*
Da Liu, *Pharm.D, Managing Director of CR-CP Life Science Fund*

3:40-3:50

Proprietary Technologies to Produce the Next Generation Growth Factors in Green Algae

Jun Wang, *Ph.D., Founder and CEO, Phycin, Frederick, MD, USA*

3:50-4:00

Immunotherapy for Solid Tumors by Chimeric Antigen Receptor (CAR)-Modified Allogeneic Natural Killer (NK) Cells

Qihong Sun, *M.D., Ph.D., Chief Medical Officer, Asclepius Technology Company Group (ATCG), Suzhou, China*

4:00-4:10

Revamping Electroporation for Fast Manufacturing of CAR-T Cells

Jian Chen, *Ph.D., Founder and CEO, Celetrix*

4:10-4:20

Stimulation of Gamma Delta T Cells for Treatment of Epithelial Solid Tumors

Jeff Galvin, *Founder and CEO, American Gene Technology, Gaithersburg, MD, USA*

4:20-4:30

Targeted and Personalized Peptide Therapy - 188 Re P2045 to Treat Lung Cancer

Christopher Adams, *CEO, Andarix Pharmaceuticals, Boston, MA, USA*

4:30-4:40

Building a China Biopharma with Distinguished Team Pipeline and Portfolios

Joan (Huaqiong) Shen, *M.D., Ph.D., Head of R&D, I-Mab Biopharma*

4:40-5:00

Panel Discussion

- **All presenters:**
- Xiaochang Dai, *Ph.D., Rotating Boulder Fun*
- Yi Dang, *Ph.D., Consultant and Investor, President of BWIA*
- Da Liu, *Pharm.D.*
- Yuanling Sun, *CEO, Marketgene Capital*

5:00-6:30

CEO Roundtable

Co-Chairs: Xurong Jiang, *M.D., Ph.D., Immediate Past President of CBA*
Dajun Yang, *M.D., Ph.D., Former President of CBA, Co-Founder, Chairman & CEO of Ascentage Pharma*

- Christopher Adams, *CEO of Andarix Pharmaceuticals*
- Hua Bai, *Chairman, Hisun Pharmaceutical*
- Jeff Galvin, *Founder & CEO of American Gene Tech.*
- Patrick Lu, Ph.D., *Founder, President & CEO of Simaomics, Inc.*
- Yingxian Xiao, *Ph.D., CEO of Shanghai Furen Medicine R&D Co., Ltd*
- Dong Xie, *Ph.D., Founder & Chairman of Frontier Biotech*
- Dajun Yang, *M.D., Ph.D., Co-Founder, Chairman & CEO of Ascentage Pharma*
- Matt Pietras, *MS, MBA, Head of Finance,Viela Bio*
- Dan Zhang, *M.D., MPH, Chairman of Fountain Medical Development*
- Xin Zhang, *Ph.D., Vice President & Global Head of DMPK, Bioanalysis & Abgent, WuXi AppTec*
- Xianshao Xiang, *CEO, Shanghai Nailii Biotechnology Engineering Co., Ltd.*
- Youbin Qiu, *General Manager of Jiangsu Huayue Medical Device Supply Chain Co.*

6:30-7:15

Reception

7:15-8:45

Dinner Banquet

Master of Ceremony (MC): Patrick Lu, *Ph.D. and Yali Fu, Ph.D.*

7:15-7:25

Opening Remarks by MC

7:25-8:40

NIH-CSSA Prize Drawings, Speech, Entertainment, Performance

8:40-8:45

Concluding Remarks

Frank Li Li, *M.D., Ph.D., CBA President (2018-2019)*

9:00

Conference / Event Concludes

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

BRILLIANT ACHIEVEMENT AWARDS

LIEPING CHEN, M.D., PH.D.
Professor, Yale University, School of Medicine

Presentation Title: Immunological Principles of anti-PD-1/PD-L1 Cancer Therapy

United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and Medicine, Yale School of Medicine; Co-Director, Cancer Immunology Program at Yale Cancer Center.
An international leader in Cancer Immunology, Dr. Chen made the landmark discovery that defined a mechanism to harness the human immune system to attack cancer (PD-1 and PD-L1), which has revolutionized cancer immunotherapy and made immune therapies a reality on a global scale. His work in the discovery of the PD-1/PD-L1 pathway in cancer therapy was cited as the #1 breakthrough of the year in 2013 by the leading international journal, Science. No less importantly, Dr. Chen is building on this success by developing new targets for cancer immunotherapy, and he is starting new biotechnology companies in Connecticut that will develop the next generation of therapies. Dr. Chen has authored more than 300 scientific publications and has served on committees and advisory boards for state, federal, and international research organizations and pharmaceutical companies. His many honors include the William B. Coley Award (2014), the AAI-Steinman Award (2016), and the Warren Alpert Foundation Prize (2017) for his world-renown discoveries. Dr. Chen was recently honored for the 2018 Luminary Award as "Father of Immunotherapy".

YONG-JUN LIU, M.D., PH.D.
Head of Research, Global R&D
Sanofi

Presentation Title: Follow the Science and Capture the Opportunity

Dr. Yong-Jun Liu is the Head of Research, Global R&D at Sanofi. He was the Head of Research and Senior Vice President of Research & Development at MedImmune (2014-2016), the Chief Scientific Officer and Vice President at Baylor Research Institute (2011-2014), Professor and Chair of the Department of Immunology, (founding) Director of the Center for Cancer Immunology Research and Vivian L. Smith Distinguished Chair in Immunology at The University of Texas M.D. Anderson Cancer Center (2002-2011). Prior to that, Dr. Liu has worked at Schering-Plough and DNAX Research Institute. Dr. Liu served as the Vice Chairman of Lianyungang Ideal Group Co., Ltd. and was a member of Scientific Advisory Board of Tanox Inc.

During his 25 years of research, Dr. Liu has made many seminal contributions to the field of immunology. He is one of the world's most prolific researchers in immunology, with over 94,000 citations (Google Scholar) and more than 250 published articles in top journals such as Nature, Science, Cell, Immunity, Nature Immunology and Journal of Experimental Medicine.

Dr. Liu has received numerous prestigious awards and honors, including the Dallas-Fort Worth Living Legend Faculty Achievement Award in Basic Research from M.D. Anderson (2009), the Dana Foundation Award for Human Immunology Research (2006), the Sandler Award for Asthma Research (2005), and the George and Barbara Bush Fellow for Innovative Cancer Research (2004).

Dr. Liu received his doctor of medicine degree in 1984 from Norman Bethune University School of Medicine in China (Jilin University), and earned his Doctorate in immunology in 1989 at the University of Birmingham in the U.K.

RICHARD PAZDUR, M.D.
Director, Oncology Center of Excellence, United States Food & Drug Administration

Presentation Title: 1971-2018: Personal Reflections on Nixon's War on Cancer

Richard Pazdur, M.D. is the director of the FDA's Oncology Center of Excellence (OCE), which leverages the combined skills of the FDA's regulatory scientists and reviewers with expertise in drugs, biologics and devices to expedite the development of novel cancer products. Pazdur previously served as the director of the Office of Hematology and Oncology Products (OHOP) in the FDA's Center for Drug Evaluation and Research since 2005 and will continue to serve in OHOP as acting director. Pazdur was the director of the Division of Oncology Drug Products from September 1999 to May 2005. Prior to joining the FDA, Pazdur was professor of medicine at The University of Texas M.D. Anderson Cancer Center from 1988 to 1999. During that time Pazdur held administrative positions of assistant vice president for academic affairs, associate director of clinical trials administration (Division of Medicine) and director of educational programs (Division of Medicine). Pazdur served on the faculty of Wayne State University, Detroit, Michigan from 1982 to 1988.

Pazdur received his bachelor's degree from Northwestern University (Evanston, Illinois), his M.D. from Loyola Stritch School of Medicine (Maywood, Illinois), and completed clinical training at Rush-Presbyterian St. Luke's Medical Center (Chicago, Illinois) and the University of Chicago Hospitals and Clinics.

Pazdur has published more than 400 articles, book chapters and abstracts. Pazdur has received numerous prestigious awards and/ honors, including "one of the 50 World's Greatest Leaders" from Fortune magazine (2015), the Distinguished Public Service Award from the American Association for Cancer Research (2015), the Service Recognition Award from the American Society of Clinical Oncology (ASCO) (2009), the Public Service Award by ASCO (2013), the Public Service Leadership Award from the National Coalition for Cancer Survivorship (2015), the Face of Hope Award from the LUNGevity Foundation (2015), and "The One Hundred" list from Massachusetts General Hospital Cancer Center (2016). Research (2015), the Service Recognition Award from the American Society of Clinical Oncology (ASCO) (2009), the Public Service Award by ASCO (2013), the Public Service Leadership Award from the National Coalition for Cancer Survivorship (2015), the Face of Hope Award from the LUNGevity Foundation (2015), and "The One Hundred" list from Massachusetts General Hospital Cancer Center (2016).

LAURENCE J.N. COOPER, M.D., PH.D.
Chief Executive Officer, ZIOPHARM Oncology

Presentation Title: The Genetic Engineering of T Cells: From Bench, to Bedside, to Boardroom

Prior to becoming the Chief Executive Officer of ZIOPHARM in May 2015, Dr. Laurence Cooper was a tenured Professor (early/exceptional promotion) at The University of Texas MD Anderson Cancer Center (MDACC), with joint appointments in the Division of Pediatrics and Department of Immunology. He also served as Section Chief of Cell Therapy at the Children's Cancer Hospital at MDACC where, as a Visiting Scientist at MDACC, he will continue to lead scientific efforts to develop new treatment approaches which pair genetic engineering with immunotherapies. Dr. Cooper has co authored dozens of peer-reviewed journal articles, abstracts, and book chapters. He has initiated multiple trials under INDs infusing T cells and NK cells. He is undertaking the first protocols using a new approach to gene therapy based upon the Sleeping Beauty transposon/transpoase system and has helped develop clinical-grade artificial antigen presenting cells for numerically expanding and activating lymphocytes. Dr. Cooper obtained his M.D. and Ph.D. degrees at Case Western Reserve University in Cleveland and then training in Pediatric Oncology and Bone Marrow Transplantation at the Fred Hutchinson Cancer Research Center in Seattle.

耐利使命
Nailii Mission

上海耐利公司专注于抗体、疫苗及仿制药产业化工程建设
Shanghai Nailii Company focuses on the construction of antibody, vaccine and generic drug industrialization Project

装备规模
Equipment Size

实验室规模、中试规模、大规模产业化系统装备
Laboratory scale, pilot scale, large-scale industrialization system equipment

服务项目
Service Items

生物产品产业化整体工艺工程设计，提供与产业化工艺相关的所有系统装备及相关配套装置，和工程安装、系统调试、功能验证、单机自控及DCS控制系统建设等一站式交钥匙服务。

The whole process engineering design of Bio-product industrialization provides one-stop turnkey service for all systems and related equipment related to industrial process, as well as engineering installation, System commissioning, function verification, single machine control and DCS system construction.

Enterprise Profile
企业简介

上海耐利公司创办于2003年5月，位于上海松江国家级经济技术开发区，公司占地面积共27700平方米，总投入2.35亿元，公司可运作人员160余人，专业技术人员55%以上，全面致力于生物医药产业工艺优化，生物工程装备的研发、设计、生产、安装、培训、服务为一体的工艺、装备、工程一体化公司。

Shanghai Nailii Ltd. Founded in May 2003, located in State-level Economic and Technology Development Zone of Songjiang, Shanghai. The company covered an area of 27,700 m2 and invested over 235 million RMB. There are over 160 staffs and over 55% of them are professionaltechnicians. The company devoted itself in biopharmaceutical industrialization and process optimization, including the development, design, production and installation of the related equipment, integrating technology, equipment and engineering together.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

SPECIAL PRESENTATION



SUJUAN BA, PH.D.
President and COO, National Foundation for Cancer Research

Session Chair

Dr. Sujuan Ba serves as the President and COO of the National Foundation for Cancer Research. She is also the founder and CEO of the Asian Fund for Cancer Research. Dr. Ba has served continuously for 13 years as co-Chair of the Prize Selection Committee of the Szent-Györgyi Prize for Progress in Cancer Research.

Dr. Ba co-founded and serves as a founding board member of the Global Coalition for Adaptive Research (GCAR), the organizing body leading the global implementation of GBM AGILE, a groundbreaking adaptive clinical trial initiative designed to produce new and better treatments for glioblastoma multiforme. She is also a co-founder of the International Cancer Impact Fund, the former President of the Chinese Biopharmaceutical Association, and serves on the International Consulting Committee of the China National Research Center for Translational Medicine (Shanghai). She also sits on the Scientific Advisory Boards of Medelis, Inc. (Fountain Hills, Arizona) and Immunicom Inc. (San Diego).

She was recognized in 2017 by the Chinese Medical Doctor Association for her outstanding contributions to international cooperation and was named one of the “Top 300 Women Leaders in Global Health” in 2015 by the Graduate Institute of International and Development Studies’ Global Health Programme.

Dr. Ba received her B.S. in radiochemistry from Peking University and her Ph.D. in chemistry from the University of

XIN ZHANG, PH.D.
Vice President & Global Head of DMPK, Bioanalysis & Abgent WuXi AppTec

Presentation Title: Creating a Pharmaceutical Innovation Ecosystem

Dr. Xin Zhang joined WuXi AppTec in September 2013. Prior to joining WuXi, Dr. Zhang worked for Charles River Laboratories, LabCorp (Tandem Labs) and Agilux Laboratories. After earning a degree in physical chemistry from Peking University and working in China for a few years, Dr. Zhang traveled to the US to pursue his graduate career and obtained his Ph.D. in organic chemistry from the University of Iowa. Dr. Zhang completed his postdoc training at Northeastern University, where he focused on new mass spectrometry applications including oligonucleotides, DNA adducts, and proteomics.

cba-usa.org

JINGYU (JULIA) LUAN, PH.D.
Team Leader, Division of Biometrics VIII, Office of Biostatistics, FDA CDER

Session Co-chair

Jingyu (Julia) Luan is a CBA board member. She joined the FDA CDER in 2006. Until 2010, she was a reviewer for neurology, cardio-renal, and psychiatry drug products in Division of Biometrics I, Office of Biostatistics. Since then, she has been a Team Leader in Division of Biometrics VIII that provides statistical support for generic drug review.

XINYU WENG, PH.D.
First Secretary of the Embassy of China to US, Primary Point of Contact for CNDA in the U.S.

Session Co-chair

Xinyu Weng, Ph.D, is First Secretary of the Embassy of the People's Republic of China to the United States of America. He is the primary point of contact for China Food and Drug Administration (CFDA) in the U.S. Before being transferred to the Chinese Embassy in Washington DC, Dr. Weng served as a Division Director in the Department of International Cooperation, CFDA since May 2013.

ALOKA G. CHAKRAVARTY, PH.D.
Acting Director of Office of Biostatistics, FDA CDER

Presentation Title: Issues in Multiregional Clinical Trials

Dr. Aloka Chakravarty is the Acting Director of the Office of Biostatistics in CDER, FDA. Dr. Chakravarty joined CDER in 1992 and brings to her current position considerable experience in CDER. She is an internationally recognized thought leader in multi-regional clinical trials, safety evaluation, surrogate markers and biomarkers in drug development and has presented and published widely on it. Her research interests include MRCTs, surrogate endpoint methodology, biomarkers, interim analysis, meta-analysis, Bayesian methodology, safety evaluation and statistical computing. Dr. Chakravarty served as an Adjunct Faculty in Department of Statistics, Foundation for Advanced Education in the Sciences, National Institutes of Health. Dr. Chakravarty has received numerous awards, including the FDA Award of Merit in 2008 and Dr. Frances O. Kelsey Drug Safety Excellence Award in 2012. Aloka received her Ph.D. in Statistics from Temple University, and Master of Statistics from Indian Statistical Institute. Dr. Chakravarty is a Fellow of the American Statistical Association and an Associate Editor of Statistics in Biomedical Research.

GANG WANG, PH.D.
Former Chief Scientist, Center for Drug Evaluation (CDE), China FDA (CNDA)

Presentation Title: CNDA's Regulatory Reform: Opportunities and Challenges

Dr. Gang Wang is former Chief Scientist in the Center for Drug Evaluation (CDE) at China FDA (CNDA). At this position, he is primarily responsible for developing, establishing and implementing the compliance and inspection program in CDE. Prior to joining CDE, Dr. Wang worked at the US FDA for 12 years. More recently, he served as Senior Policy Advisor in the Office of Manufacturing Quality (OMQ), Office of Compliance in CDER. He provides advice on policy, regulation, compliance and international affairs related issues to the senior management in the Office; Assistant Country Director of the FDA China Office in the US Embassy Beijing, responsible for policy analysis, outreach and capacity building in the drug portfolio, and collaboration between US FDA, CFDA, pharmaceutical industry and other stakeholders; Senior Reviewer/Expert Biologist/ Lead Inspector of the Office of Compliance and Biologics Quality (OCBQ) in CBER, responsible for CMC reviews and pre-license and pre-approval inspections for biologics regulated by CBER. Dr. Wang is a peer-reviewed expert in biologics manufacturing and CGMP, especially in the area of cell and gene therapy product manufacturing, regulation and supervision.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

GLOBAL DRUG DEVELOPMENT: ICH AND ROLE OF CHINA



DAN ZHANG, M.D.
Executive Chairman of Fountain Medical Development Ltd

Panelist

Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd, a clinical CRO with 1700 employees operating in China, Hong Kong, Taiwan, South Korea, Japan, UK, India, Philippines, Armenia & USA. Dr. Zhang is a member of ICH E19 Expert Working Group. He is a member of grant review committee for National Drug Development Fund of China, and is also a consultant for the CFDA.

BILL WANG, PH.D..
Executive Director, Clinical Safety Statistics, Merck & Co Inc.

Panelist

Dr. William (Bill) Wang is executive director, clinical safety statistics, in the department of Biostatistics and Research Decision Sciences (BARDS), Merck Research Laboratories. He has over 25 years of experience in the pharmaceutical industry, with expertise and research publications in statistical design, analysis, clinical data management and their technology enablement.

SHOUBAI CHAO, PH.D.
Chief Operating Officer, CanSino BIO

Panelist

Dr. Shou-Bai Chao is former president of Chinese Biopharmaceutical Association. He is currently Chief Operations Officer at CanSino BIO. Prior to joining CanSino BIO, Dr. Chao was Senior Vice President at AstraZeneca leading AstraZeneca's BioVentures business unit to develop Biosimilars and BioBetters for global markets with leading biotech companies in China and other Asian countries.

HELEN H. MAO, PH.D., MBA
Co-founder and Senior Vice President
CanSino Biologics

Session Chair

Dr. Mao is Co-founder and Senior Vice President of CanSino Biologics Inc. which specializes in the development and commercialization of innovative vaccine products. In October 2017, CanSino Biologics successfully developed an Ebola Virus Disease Vaccine (EBOV), and obtained new drug approval from CFDA. Dr. Mao is Adjunct Professor of Tianjin University of Sciences and Technology and Nankai University. Dr. Mao is currently a Board of Director with Chinese Biopharmaceutical Association (CBA-US) and a member of BayHelix Association.

LILI QI
Assistant Chief Administrative Officer, Montgomery County Executive Office, Maryland

Presentation Title: Biotech and Montgomery County's Economy

Lily Qi is Assistant Chief Administrative Officer for economic and workforce development responsible for the County's overall economic strategies, business climate issues, economic communication and strategic partnerships with key organizations and institutions. She has served County Executive Ike Leggett for eight years in various capacities and led strategic initiatives including privatizing economic development functions; establishing BioHealth Innovation, Inc. to advance research commercialization; developing global partnerships; improving nighttime economy, and developing the Comprehensive Economic Strategy. Lily joined Montgomery County after serving as Vice President of Business Development and Marketing for the Washington, DC Economic Partnership and spokesperson for the DC Department of Insurance, Securities and Banking.

A native of Shanghai, China, Lily is also a writer, speaker and trainer on cultural competency and immigrant integration issues. She was featured in the Washington Business Journal, Bethesda Magazine, China Daily, and Asian Fortune for her professional accomplishments and community leadership, which includes encouraging civic and political engagement of immigrant communities and serving as trustee of the Suburban Hospital of Johns Hopkins Medicine, and immediate past chair of the Maryland Governor's Commission on Asian American Affairs.

ZHE ZHI
Vice General Manager, China Resources Life Science Park Company

Presentation Title: Incubating Future Innovators and Entrepreneurs in Life Sciences

Mr. Zhi is the Vice General Manager of China Resources Life Science Park Company (CRLSP) and assistant general manager of Strategy Management Department of China Resources Group. He is in charge of the business development, finance, human resources of CRLSP.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

ENTREPRENEUR INCUBATORS & COLLABORATION



JIANNING LI
TEDA U.S. Office

Presentation Title: N/A (Video provided for TEDA)

Mr. Jianning Li is the Chief Representative of TEDA U.S. Office based in Chicago, IL since August 2006. Before that, Mr. Li worked as Senior Project Manager of TEDA Investment Bureau from 2001 to 2005, and Section chief of TEDA City Development Bureau from 1997 to 2001. Mr. Li has Bachelor degree on Mechanical Engineering from Beijing Institute of Light Industry (from 1989 to 1993) and Master degree of Finance from Tianjin University of Economics and Finance (from 1997 to 1998). Mr. Li also got his MBA diploma from West Virginia University (from 2005 to 2006). Mr. Li's current major role is to help the U.S. companies expand their business in China, including direct investment, franchising, seeking partners, outsourcing and marketing. Mr. Li also helps many Chinese companies to make investments in the U.S.

FELICIA PULLAM
Regional Manager, East Asia & Investment Team Lead
Office of International Investment & Trade, MD Department of Commerce

Presentation Title: Maryland Resources for Business Growth

Felicia Pullam is the Regional Manager for East Asia for the Office of International Investment and Trade, Maryland Department of Commerce, where she helps Maryland companies export to China, Taiwan, Japan, and South Korea. She also assists foreign companies that are interested in establishing operations in the state. Before joining the Maryland team, Felicia was the Deputy Assistant Secretary for Textiles, Consumer Goods, and Materials at the U.S. Department of Commerce. She also served as the Director of Outreach for SelectUSA, the federal program to promote foreign direct investment (FDI) into the United States. Prior to her federal service, Felicia helped lead trade and FDI for the State of Delaware. She got her start in international affairs in 2000 through the Princeton in Asia program in Guangzhou, and then spent a year as tutor and translator for Chinese actress Zhang Ziyi. She proceeded to spend nearly a decade in Asia managing APCO Worldwide's regional Corporate Responsibility and Sustainability practice.

SARAH MILLER
VP and Chief of Staff
Montgomery County Economic Development Corporation, MD

Presentation Title: Supporting Entrepreneurs in a Sustainable Local Economy

Sarah is MCEDC's Vice President & Chief of Staff. She has worked in community and economic development in Montgomery County and across Pennsylvania for the past 18 years. She has created riverfront parks, supported new farms, kick-started incubators and engaged civic leaders as they reimagined their former industrial towns. Wherever she is, Sarah's professional goal remains the same — to provide people with access to new economic opportunities.

Formerly, Sarah was Special Assistant to the Secretary in the Pennsylvania Department of Community and Economic Development, Capital Projects Manager for the Department of Economic Development in Montgomery County, and spent many years working in Pittsburgh. A graduate of Ohio University, where she studied community health, she also received a master's degree from Carnegie Mellon University in Public Policy & Management, with a concentration in economic development. Sarah currently serves on the Rockville Planning Commission, the Montgomery County Food Council and also on the incubator committee for Bethesda Green. She lives in Rockville with her husband and son.

ALEX WANG
Director of Maryland International Incubator (MI2), University of Maryland at College Park

Presentation Title: Introduction of Maryland International Incubator

Alex brings 15 years of experience in management consulting, business startups, overseas investment, and healthcare industry. For the past eight years, he has managed complex projects for some of the most innovative companies, including Fortune 500 firms. Unlike many business professionals, Alex brings a strong sciences and technology background to inspire his business solutions. He worked at Ernst & Young Life Sciences Consulting Division (New York City), Mt. Sinai Hospital (New York City), and Zhongxin Pharmaceuticals (Tianjin, China). He served as a senior executive of a nanotechnology startup company. In his own time, Alex serves as a professional interpreter for Chinese hospital presidents and manages their network event with American hospital executives since 2009.

Alex received his Ph.D. from University of Pennsylvania School of Medicine (cell & molecular biology major), and an MBA from University of Notre Dame (consulting major).

MITCHELL HO, PHD
Senior Investigator, Laboratory of Molecular Biology, National Cancer Institute; Chair, Department of Biochemistry, FAES Graduate School NIH

Presentation Title: CAR T-Cells Targeting Glypicans in Cancer

Dr. Ho is an internationally renowned expert in the field of antibody engineering and therapeutics. Antibody-based therapeutics is a major component in the cancer treatment landscape. However, for many cancers we know little about what shared tumor antigens can be safely and effectively targeted in many patients to discriminate cancers from normal tissues. Dr. Ho and colleagues have conducted pioneer studies of cell surface glypicans GPC2 and GPC3 as co-receptors for Wnt/Yap signaling molecules and as new targets for antibody-based immunotherapy in solid tumors. His research also demonstrates that 'single domain antibodies' can modulate key signaling processes responsible for cancer development by binding buried protein clefts that are unreachable by conventional antibodies. By targeting tumor specific glypicans, his lab has developed new CAR T-cell immunotherapy for treating liver cancer, childhood cancers and other cancers. Dr. Ho has received many honors including APAO Scientific Achievement Award, NCI Director's Intramural Innovation Award and NIH Deputy Director for Intramural Research Innovation Award. Dr. Ho serves on many editorial, review and advisory committees. He is the Editor-In-Chief for the new international journal 'Antibody Therapeutics' (Oxford), a distinguished advisor for the Antibody Society and the Chair of the Scientific Advisory Board for Chinese Antibody Society.

CHI MA, PHD
Staff Scientist, Thoracic and Gastrointestinal Oncology NCI, NIH

Presentation Title: Gut Microbiome Controls Liver Tumor Growth via Bile Acid-regulated NKT Cells

Chi Ma M.D. PhD received his medical degree at JiNing medical college in Shandong, China in 2001. He did his PhD training (2001-2007) in Sun Yat-sen University working on signal transduction, followed by 3-year postdoctoral fellowship at University of Texas at Dallas. In 2011, Dr. Chi Ma moved to NIH and joined the laboratory of Tim Greten and started his work in the field of tumor immunology as a postdoctoral fellow. He found that the nonalcoholic fatty liver disease causes selective CD4+ T cell loss and impairs live anti-tumor surveillance (Nature 2016). His recent work discovered that gut commensal bacteria can use bile acids as messenger to regular liver anti-tumor immunity thus modulate liver tumor development (Science 2018). In 2016 Chi Ma was promoted as staff scientist.

WANJUN CHEN, M.D.
Senior Investigator, Chief, Mucosal Immunology Section, NIDCR, NIH

Presentation Title: T Regulatory Cells for Immunotherapy to Autoimmunity and Cancer

Dr. Chen is an internationally recognized immunologist at NIDCR, NIH. His research focuses on elucidating mechanisms of T-cell immunity and tolerance and manipulating T-cell immunity versus tolerance in animal models to understand the pathogenesis of and develop immunotherapy for autoimmunity, cancer and infectious diseases. Dr. Chen is the first who discovered that TGF-beta induces Foxp3 gene in naive CD4+ T cells and converts them into regulatory T cells (iTregs). This finding was praised by NIH Intramural Director Dr. Michael Gottesman as "revolution" and has been cited for more than 4000 times and ranked as the 3rd of 50 most cited papers published on J. Exp. Med. Dr. Chen has also discovered a way to induce autoantigen-specific regulatory T cells in vivo after the animals were developed diseases in experimental models of autoimmunity including EAE, type I diabetes and rheumatoid arthritis, which opens a way to develop immunotherapy for human autoimmune diseases and cancer. The discovery has been commented by Science and covered by several news agencies including Xinhua News. Most recently, Dr. Chen has discovered that D-mannose induces generation of regulatory T cells and suppresses autoimmune diabetes and asthmatic lung inflammation. Dr. Chen has published more than 100 peer-reviewed articles in internationally prestigious journals including Nature, Nature Medicine, Nature Immunology, Immunity, J. Exp. Med., PNAS, Science Translational Medicine, Cell Stem Cell etc., and been invited to speak at many international meetings and universities in the world.

Dr. Chen received many honors and awards, including the Scientific Achievement Award from the NIH Asian and Pacific Islander American Organization and the Wang Ying-Lai Memorial Lecturer. In addition to his scientific activities, Dr. Chen was also the elected president of the Society of Chinese Biologists at America (SCBA) Washington-DC-Baltimore Chapter in 2015.

创新，创业，创机遇，迎接全球生物制药新时代
Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development
ARTIFICIAL INTELLIGENCE & BIG DATA IN BIOPHARMACEUTICAL DEVELOPMENT

CHUANHUA (JULIA) XING PH.D.
Vice President, CBA-USA
Founder, XPrecision LLC & ShiHua Big Data Healthcare

Session Chair

Dr. Chuanhua Julia Xing is the founder of XPrecision LLC and ShiHua Big Data Healthcare (Shenzhen, China), focusing on the development of artificial intelligence products with applications to disease prediction, diagnosis, treatment and management and drug development. She is also Vice President and board member of Chinese Biopharmaceutical Association, visiting professor of Sun Yat-Sun University, member of Precision Medicine Advisor Committee for Beijing Health Promotion Association etc.

QINGSONG ZHU, PH.D.
Chief Operating Officer
Insilico Medicine, Inc

Presentation Title: Application of Deep Learning in Drug Discovery

Qingsong Zhu, Ph.D. is the Chief Operating Officer of InSilico Medicine, Inc., a company that utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and biomarker development for aging and age-related diseases. Dr. Zhu received his Ph.D. degree in biochemistry from Kansas State University. He was interested in integrating biochemistry, genomics, and bioinformatics to develop new targets for insect control. Prior to joining Insilico Medicine, he received his postdoctoral training at Johns Hopkins University School of Medicine under the supervision of Dr. Nancy Davidson. When he worked at Johns Hopkins University, his research focused on cancer epigenetic biomarker and anti-epigenetic cancer drug development. He is currently interested in applying deep learning to early diagnosis biomarker development and drug discovery for cancer and other age-related diseases.

NATHAN SALMON
Chief Architect
MetiStream

Presentation Title: Burn the Haystack!: Finding the Needle in Clinical Notes and Genomics at Scale

Nathan Salmon is MetiStream's Chief Architect and visionary for Ember, an intuitive healthcare analytics solution leveraging FHIR and Spark. He brings deep domain expertise in healthcare from his early career at Cerner and extensive experience in big data technologies such as Spark, Kafka, Solr, and HBase. Nathan has architected and implemented streaming, search, analytic, and storage solutions for companies such as Cerner, Global Wireless Solutions, Evariant, and Bose Corporation. As a contributor to Open Source projects such as Samza and Impala and a regular speaker at many technology meetups, he is passionate about Open Source and regularly gives back to the community. Away from the keyboard, Nathan enjoys practicing kenpo, jamming out with other musicians, and belting it out at karaoke.

SHIHCHUNG BENEDICT LO, PH.D.
Georgetown University Medical Center & Virginia Tech

Presentation Title: Deep Learning Convolutional Neural Networks Techniques and Their Applications in Biomedical Sciences - A Successful Example in Lung Imaging

ShihChung Benedict Lo received his Ph.D. in Medical Physics from University of California, Los Angeles in 1986. He then worked at Philips Medical Systems Inc. as an MRI & CT scientist. In 1987 he joined Center for Imaging Sciences and Information Systems (ISIS) at Radiology and Oncology Departments of Georgetown University as a Research Professor for 27 years. Dr. Lo was one of earliest researchers in deep learning convolutional neural networks (CNN) since early 1990s. He also invented wavelet CNN (1995) and circular CNN (1998), isotropic CNN and has performed research in optimization of wavelets and filter bank unification theory through CNN. Since early 1990s, he has collaborated with industrial partners and has produced more than 10 FDA cleared AI products for effective detection of early stage lung cancer and lung diseases. In 2014, he moved to Arlington Innovation Center: Health Research, Virginia Tech.

REAL WORLD EVIDENCE MEDICINE IN BIOPHARMACEUTICAL DEVELOPMENT

YIFAN ZHAI, M.D. PH.D.
Chief Medical Officer
Ascentage Pharma

Session Chair

Dr. Zhai is Chief Medical Officer at Ascentage Pharma, responsible for pre-clinical and clinical development of all company's potential drugs. She has more than 25 years of experience in cancer research and new drug development in multiple therapeutic areas including cancer, cardiovascular, metabolic diseases, autoimmune diseases and immunotherapy. Dr. Zhai served as President of the Chinese Biopharmaceutical Association-USA (CBA) in 2009 – 2010.

SEAN KHOZIN, MD, MPH
Acting Associate Director, OCE
FDA

Presentation Title: Information Exchange and Data Transformation (INFORMED)

Dr. Sean Khozin is Acting Associate Director at the FDA's Oncology Center of Excellence, and he is the founding director of Information Exchange and Data Transformation (INFORMED), an incubator for collaborative regulatory science research focused on supporting innovations that enhance the agency's mission to promote and protect public health. INFORMED is expanding organizational and technical infrastructure for big data analytics and examining modern approaches in evidence generation to support regulatory decisions.

Previously, Khozin was in private practice in New York City, an attending physician at St. Vincent's Hospital in Manhattan and an entrepreneur specializing in building health information technology systems with virtual patient management and point-of-care data visualization and analytics capabilities. Khozin received the 2017 Charles A. Sanders Life Sciences Award (accepted on behalf of the FDA), the 2017 FDA Commissioner's Group Award for the Naloxone App Challenge, and the 2004 Abraham Lilienfeld Award in biostatistics and advanced analytics.

IKSHA HERR
RWE Data & Analytics Leader
AstraZeneca

Presentation Title: Realizing the Potential of Real World Data and Evidence

Iksha Herr joined AstraZeneca in January 2017 and in her role as the Real World Evidence Data & Analytics Director, develops and executes Real World data, technology, and analytics related strategic projects. Prior to joining AstraZeneca, Iksha led real world data and analytics projects for pharmaceutical / biotechnology companies and management consulting projects for Booz Allen Hamilton. Her work at Booz Allen Hamilton focused on providing strategic roadmaps to federal government healthcare agencies using real world data and evidence, leveraging Big Data technology and platforms.

Iksha received a Bachelor's degree in Polymer Engineering from Pune University in India and a Master of Science degree in Computer Science from New Jersey Institute of Technology, New Jersey.

XIA WANG, PH.D.
Director, Health Informatics
AstraZeneca

Panelist

Xia holds a Director position at Health Informatics group within the AstraZeneca clinical development. Xia has records of accomplishment in applying novel informatics solutions and real world data analytics to all phases of medicines development life cycles, spanning diabetes, respiratory and autoimmune therapeutic areas. Currently Xia is leading informatics efforts in AstraZeneca Real World Evidence (RWE) to support clinical and observational studies, medicines comparative effectiveness, payer & pricing strategy and marketing accessing research.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

ENTREPRENEURS AND INVESTORS



DA LIU, PHARM.D
Managing Director of CR-CP
Life Science Fund

Session Chair

Mr. Liu is Managing Director of CR-CP Life Science Fund, CR and CP are global fortune 500 companies. Prior to current position, he was strategic business director at China Resources Group, senior director of CR Pharmaceutical Group and vice-president of Beijing Pharmaceutical Inc, Co.. Before returned to China, he had worked for CVS, Novo Nordisk and New York Healthcare Corp. Mr. Liu was a licensed pharmacist in the state of New York.

DAZHI LAI, PH.D.
Board Director of CBA, Founder
of Magnifygen Inc,

Session Co-Chair

Dazhi (Alex) Lai graduated from Nankai University. He received his Ph.D. in Biotechnology from the Academy of Military Medical Sciences of China. He continued his postdoctoral research at Yale University and the NIH. In 2012, he founded SPEED Biosystems, a supplier of biomedical reagents, materials and equipment, and served as its Marketing Director and CEO since then. In 2014, he founded Magnifygen Inc, a startup focused on development of antibody drugs against breast cancer.

JUN WANG, PH.D.
Founder and CEO, Phycin, LLC.,
Frederick, Maryland, USA

Presentation Title: Proprietary Technologies to Produce the Next Generation Growth Factors in Green Algae

Dr. Wang founded Phycin in 2013 to produce the human growth factors in green algae, in order to meet the demands from stem cell, regenerative medicine and aesthetics industries, for growth factors that are free of bacterial endotoxin and potential pathogenic viruses, at much lower cost. No any other production platform is able to fulfill all these requirements. Jun was named 2015 "People to Watch" by Frederick Magazine. Phycin was chosen as a 2015 Maryland Incubator Company of the Year Finalist. Phycin was awarded Maryland Stem Cell Research Fund and TEDCO Technology Development Fund.

Dr. Wang graduated from Lanzhou University. He received his postdoctoral training at Max-Planck Institute for Biochemistry, and later at the Ohio State University. Dr. Wang worked as the science leader at pioneering algal biotechnology companies including Martek Biosciences Inc., where he utilized algae as the platform to produce high value, health beneficial proteins.

QIHONG SUN, M.D., PH.D.
Director, Health Informatics
AstraZeneca

Presentation Title: Immunotherapy for Solid Tumors by Chimeric Antigen Receptor (CAR)-modified Allogeneic Natural Killer (NK) Cells

Dr. Sun has a comprehensive medical background and extensive research experience. He received Bachelor of medicine, Master of pathology and Doctor of surgery (tutored by Academician Wu Mengchao), and completed a postdoctoral study of cell biology in the United States. Dr. Sun has been engaged in oncology and immunology for 30 years. He worked as a Professor, Doctoral Tutor in immunology and Director of Immunology Laboratory in the Academy of Military Medical Sciences, a Postdoctoral Scholar and Research Scientist at the Blood Center of Wisconsin, Assistant Research Professor at the State University of New York, Assistant to the Director of Beijing Proteome Research Center (BPRC), Director of International Cooperation Department and Principal Investigator (P.I.) of Antibody Engineering Laboratory at BPRC. He was also an Assistant to the President of the international Human Liver Proteome Plan, the Sub-committee Chairman of the international Human Liver Proteome Antibody Project and a Standing Council Member of the Chinese Human Proteome Organization. Dr. Sun received funding independently from American Heart Association (AHA), and his research projects were supported by National 973, 863, and NNSF in China. He has 100 publications, including more than 20 peer reviewed papers in JBC, Blood, JI and PNAS. He also successfully applied for patent "The hybridoma cell line and its anti human VEGFR-3 monoclonal antibody (200510127745.5)." Currently Dr. Sun is the Partner, Partner, Vice-President and Chief Medical Officer at Asclepius Technology Company Group (ATCG) in Suzhou, and responsible for the production, quality control and clinical application of CAR-NK for cancer immunotherapy.

ZHAI YIFAN, M.D. PH.D.
Founder & CEO
Celetrix

Presentation Title: Revamping Electroporation for Fast Manufacturing of CAR-T Cells

BS, Biology, Tsinghua University 1997
PhD, Pharmacology, Cornell University/MSKCC 2004
Postdoc, UCSD (2004-2005) and Mount Sinai (2006-2010), Immunology

Celetrix is at the frontier of next-generation immunotherapy technologies with the new high efficiency electroporation technologies. Electroporation is an important method for delivering macromolecules such as DNA and proteins to the cells. While other existing electroporation had difficulties in expressing CAR molecules in T cells, Celetrix technology allows T cells to express CAR at high efficiency with optimal cell survival. The Celetrix electroporation technology is poised to disrupt the viral-vector delivery market with the low cost and higher efficiency. Celetrix has issued patents in the US, China and Japan and more pending patent applications worldwide.

JEFF GALVIN
CEO and Founder, American Gene Technologies

Presentation Title: Information Exchange and Data Transformation (INFORMED)

Jeffrey A. Galvin is the CEO and Founder of American Gene Technologies (AGT). He earned his BA degree in Economics from Harvard in 1981 and has more than 30 years of business and entrepreneurial experience including founder or executive positions at a variety of Silicon Valley startups. Several of his companies were taken public and/or sold to public companies, including one in the medical-technology arena that was sold to Varian, the leading maker of linear accelerators used in cancer therapy. Following his startup experience, he retired to become an Angel Investor in real estate and high tech. He came out of retirement to found and fund AGT after meeting Roscoe Brady at NIH.

CHRISTOPHER P. ADAMS
Founder and CEO,
Andarix

Presentation Title: Targeted and Personalized Peptide Therapy - 188 Re P2045 to Treat Lung Cancer

Mr. Adams has been a founder or co-founder of life science and technology based companies in Massachusetts for the past several years. Mr. Adams has been instrumental in developing new proprietary therapeutic and medical device technologies and bringing the technologies to commercialization. The companies he has founded include, Compellis Pharmaceuticals, a developer of therapeutics to treat obesity and its comorbidities, diabetes and hypertension and Mosaic Technologies, a venture backed MIT spin-out genomics company that developed patented technologies for genetic analysis and detection. Mr. Adams is the inventor on more than 20 patents.

YUANLING SUN
CEO, Founder, Marketgene Capital Ltd.

Panelist

Yuanling Sun, from Chengdu, had studied and worked in Japan from 1997 to 2013. With more than 15 years of experience in the financial industry, she is good at international capital operation, and be familiar with the secondary and primary financial market. She has been responsible for a number of investment and asset management companies, including as the CEO of Marketgene Capital(China), and the chairman of Jiading Investment Co., Ltd. She owned the excellent Sichuan businesswoman in 2016, and has served as the vice president of National Youth Sichuan Business Council and Sichuan Female Business Council (2017), and the president of the East Magnolia Hui in Sichuan branch.

创新，创业，创机遇，迎接全球生物制药新时代
Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development
ENTREPRENEURS AND INVESTORS

JOAN (HUAQIONG) SHEN, MD, PHD
Head of Research & Development,
I-Mab Biopharma Co.

Presentation Title: Building a China Biopharma with Distinguished Team, Pipeline and Portfolios

Joan obtained PhD in life science and license as a physician with board certification in US. She also had 3 postdoctoral trainings in endocrinology, psychopharmacology and clinical pharmacology. She practiced as a psychiatrist and worked in Eli Lilly & Co, Wyeth and Pfizer, where she was responsible for global clinical development programs cross phase 1-4. She has extensive experiences working with FDA, EMEA, CFDA, PMDA, KFDA and etc. She holds academic positions as the guest professor of Beijing University Clinical Research Institute and adjunctive professor of Indiana University School of Medicine.

Joan was sent to China by Pfizer in 2011 as the China clinical head and joined Hengrui as the CMO in May 2013. She was granted the honor of “Talent of Innovation” by the “National Thousand Talent Program”. In Hengrui, she built the largest clinical team among China domestic pharmas and led the successful conduction of clinical trials in China, USA and Australia. She is also elected as the executive committee member of China New Drug Research Evaluation Committee. Joan joined Janssen Pharmaceutical Companies of Johnson & Johnson as the China development head in 2015 and responsible for all the development programs, where she led multiple successful NDA approvals by CFDA. During this time, she is elected as the co-chair of RDPAC R&D core team. Most recently Joan joined I-Mab biopharma as the head of R&D and is leading the efforts of China to China and China to global.

XIAOCHANG DAI PH.D
Chief investment officer of Rotating Boulder Fund

Panelist

Dr. Xiaochang Dai is the chief investment officer of Rotating Boulder Fund. The fund has a focus on biopharm sector on both sides of Pacific. He is a leading figure in the Chinese pharmaceutical industry in the past two decades. Dr. Dai received his Ph.D. from The Scripps Research Institute and his postdoctoral training from California Institute of Technology. Since his return to China in 1999, Dr. Dai has held a series of executive positions.

YI DANG, PHD
Consultant and Investor,
President of BWIA LLC

Panelist

In recent years, Dr. Dang have been interested in understanding and investing in biopharma after have spent decades working with start-up and established pharmaceutical companies. He is an active learner and reader, researching and analyzing corporations quantitatively and qualitatively. He has been influenced by well known value investors and some hedge fund managers. He is also a successful real estate investor. Dr. Dang earned a Ph.D. and Masters degrees in Organic Chemistry. He is an author of numerous technical and non-technical publications. Locally he has been active in volunteering to support sciences, education, and active-living projects and activities. He is a marathoner and ultra-runner.

XURONG JIANG, M.D., PH.D.

Session Co-Chair

DAJUN YANG M.D., PH.D.
Chairman and CEO, Ascentage Pharma

Session Co-Chair

Dr. Yang co-founded Ascentage Pharma Group in 2010, and is the Chairman & CEO since then. Dr. Yang has established a China-based R&D team with international standards with several targeted oncology therapeutic NCE compounds in phase I and phase II trials in US, Australia and China. Before Ascentage Pharma, Dr. Yang co-founded Ascenta Therapeutics in 2003, where he was Senior VP of Research and preclinical development, and completed near US$100 million financing with six top-tier biotechnology venture capital investors in US. Previously, Dr. Yang served as an Associate Professor of Internal Medicine in the Comprehensive Cancer Center at the University of Michigan. In 1995, he joined the Georgetown University Medical Center (GUMC) as an Assistant Professor in the Department of Biochemistry and Molecular Biology, and a Senior Investigator in the Lombardi Cancer Center, which he assumed in 1999 and promoted to Associate Professor in 2001.

MATT PIETRAS, MS, MBA
Head of Finance
Viela Bio

Panelist

Matt Pietras is the Head of Finance at Viela Bio. Matt is a Certified Public Accountant, and has his MBA and a Masters Degree in Biotechnology, both from Johns Hopkins University. Prior to joining Viela Bio, Matt was the Finance Director responsible for overseeing AstraZeneca's Oncology pipeline and the Cancer Enterprise. Prior to joining AstraZeneca Matt spent nearly a decade in banking with Wells Fargo and Wachovia. Matt started his career with the Audit and Advisory practice of KPMG.

YINGXIAN XIAO, PH.D.
CEO of Shanghai Furen Medicine R&D Co., Ltd.

Panelist

Dr. Yingxian Xiao is the founding CEO of Shanghai Furen Medicine R&D Co., Ltd. and has served as CEO and General Manager of the company since 2015. He received his B.S. in microbiology from Northwestern University and his M.S. in microbiology from Institute of Microbiology, Chinese Academy of Sciences. He studied molecular biology and biotechnology at the University of Maryland at College Park and received a Ph.D. in 1994. After a three-year Post doctorate in molecular pharmacology at Georgetown University, working on pharmacological properties of neuronal nicotinic acetylcholine receptors, he joined the faculty of Georgetown University School of Medicine in 1997 and worked in Department of Pharmacology until June 2016. Dr. Xiao's research interests are on molecular pharmacology of nicotinic receptors, mechanism of ligand-receptor interactions and developing new CNS therapeutics targeting nicotinic receptors. He has authored and co-authored more than 70 peer-reviewed papers. Dr. Xiao was a founding member of the Chinese Biopharmaceutical Association – USA (CBA) in 1995. He has served as a member of CBA Board of Directors since 1997. Dr. Xiao served as the CBA president from 2003 to 2004. He was the recipient of 2008 CBA Outstanding Service Award.

XIANSHAO XIANG
CEO
Shanghai Nailii Biotechnology Engineering Co., Ltd.

Panelist

Mr. Xianshao Xiang co-founded Shanghai Nailii in 2003 and was responsible for building up relationships with high- end international bio-pharmaceutical companies, research institute and universities. He has participated in the construction of National livelihood projects as well as the "863" project in the "12th Five-Year" Plan: Research and development of key process technology on large scale mammalian cell culture in bioreactor, development and manufacturing of production scale bioreactor for cell culture. Mr. Xiang majored in mechanical automation and is now be responsible for the research of the new device and process technologies in bio-pharmaceutical field. He has already successfully applied micro-carrier suspension culture technology in 2000L bioreactor. Mr. Xiang owned multiple patents in fields of cell culture and its related equipment, and has 19 years of experience in equipment manufacturing, automation designing and production management.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CEO ROUNDTABLE



DONG XIE, PH.D.
Founder, Chairman & Chief Scientific Officer, Frontier Biotech

Panelist

Dr. Xie is the Founder, Chairman and CSO of Frontier Biotech,a research-based, clinical stage pharmaceutical company utilizing cross-Pacific drug discovery and development business model. Prior to co-founding Frontier Biotech in 2002, Dr. Xie was Director of Research of Tibotec Inc., the US subsidiary of Tibotec NV (acquired by J&J in 2002). He was Head of Biophysics Laboratory at the NCI-Frederick Cancer Research and Development Center from 1995 to 2000, and Director of Operation of the Biocalorimetry Center at The Johns Hopkins University from 1993 to 1995. Dr. Xie received his B.S. degree in Physics from Peking University and Ph.D. degree in biophysics from The Johns Hopkins University. Dr. Xie is a member of China National "Thousand Talent Program".

HUA BAI
Chairman, Zhejiang Hisun Pharmaceutical CO. LTD.

Panelist

Mr Bai Hua joined Zhejiang Hisun Pharmaceutical CO. LTD. in 1968 and became the president in 1981 and promoted to be the chair since 1998. Mr Bai Hua served Hisun Pharm for 50 years is definitely a legendary in Chinese Domestic Pharmaceutical Industry. He himself was awarded "Top 100 Global Pharmaceutical elites", "National Medicine Outstanding Entrepreneurs", "Chinese Medicine Enterprises Outstanding leader", "Chinese Medicine 60 Years 60 People", " Top 10 Innovation Characters of China Industry Brands " etc., and several Zhejiang province awards. He was also the representative of Chinese pharmaceutical industry accompanied national leaders to APEC meetings for six times.

Mr Bai Hua started as Professional Engineer. The strong research and technical background to make him a major Committee in national drug discovery at the ministry of science and technology, and one of the outstanding entrepreneurs in China's modern pharmaceutical industry.

PATRICK Y. LU, PH.D,
Founder, President and CEO of Sirnaomics, Inc.

Panelist

Dr. Lu started his biopharmaceutical industry career in 1993 and served as a lab head and senior scientist in Novartis and Digene (until 2000). Dr. Lu was the co-founder and Executive Vice President of Intradigm Corporation (2001-2006). Patrick has authored more than 50 scientific papers, review articles and book chapters, and holds 35 issued and pending international patents. He has been an invited speaker in many international conferences throughout the world. Dr. Lu has been awarded a number of grants from NIH, the State and County governments, and he is also a "1000 Talents" Expert, and Adjunct Professor of Nanjing University and South China University of Technology.

YOUBIN QIU
General Manager of Jiangsu Huayue Medical Device Supply Chain Co.

Panelist

Mr. Qiu is the general manager of Jiangsu Huayue Medical Device Supply Chain Co. Ltd., which focuses on medical device supply chain management and service. The company is responsible to build comprehensive service platform for medical device companies.

Additional Panelists

DAN ZHANG, M.D.
CHRISTOPHER P. ADAMS
JEFF GALVIN
XIN ZHANG, PH.D.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA ACTIVITIES 2017-2018

cba-usa.org

Photos from 2017 Annual Conference

Photos from 2017- 2018 CBA Workshop

UPCOMING CBA ACTIVITIES (2018-2019)
SAVE THE DATE

cba-usa.org

- **August 2018** - Workshop
- **September 2018** - Autumn Picnic
- **October 2018** - Workshop



- **January 2019** - Workshop
- **February 2019** - Chinese New Year Gala
- **April 2019** - Career Development Workshop
- **8-9 June 2019** - the 24th Annual Conference

cba-usa.org

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA PAST 10-YEAR AWARD RECIPIENTS

The CBA Brilliant Achievement Award Recipients

The CBA Brilliant Achievement Award was established in 2003 to honor outstanding individuals who have made seminal contributions to science, technology, or business development in the biopharmaceutical fields; whose vision has moved medicine in new directions; and who has been actively involved in building collaborative efforts internationally to advance medical fields. The Award also aims to promote public awareness of the importance of collaborations between basic and applied researchers, between academia and industry, and between researchers and entrepreneurs.

2017 **ROBERT TEMPLE**, M.D., Deputy Director of Clinical Science, FDA CDER

J. CRAIG VENTER, Ph.D., Executive Chairman, Human Longevity, Inc., Founder, Chairman, and CEO of the J. Craig Venter Institute, Co-Founder, Executive Chairman, and Co-Chief Scientist of Synthetic Genomics Inc.

2016 **BAHIJA JALLAL,** Ph.D., Executive Vice President of AstraZeneca and Head of MedImmune

GE LI, Ph.D., CEO and Chairman of Board of Directors, WuXi AppTec

2016 **ZHU CHEN,** Ph.D, Vice-Chairman, 12th Standing Committee of the NPC; Chairman, 15th Chinese Peasants and Workers Democratic Party, Member of Chinese Academy of Sciences, Foreign member of the United States National Academy of Sciences

2015 **BARRY K.** Sharpless, Ph.D., 2001 Nobel Laureate for Chemistry, member of the United States National Academy of Sciences, W. M. Keck Professor of Chemistry at The Scripps Research Institute

CHEN KAIXIAN, Ph.D., Member of Chinese Academy of Sciences Professor, Shanghai Institute of Materia Medica, Chinese Academy of Sciences 2015 CBA Lifetime Achievement Award

PIAOYANG SUN, Ph.D., Chairmen, Jiangsu Hengrui Medicine CO, LTD, CBA Outstanding Contribution Award

YANGHAO CHEN, Deputy Director, Guangdong Overseas Chinese Affairs Office, CBA Extraordinary Support Award

2014 **JAMES F. YOUNG**, Ph.D., Chairman, Board of Directors, Novavax, Inc.

2013 **JAMES L. HUGHES**, MBA, Vice President, Chief Enterprise Economic Development Officer, President, UM Health Sciences Research Park Corporation, University of Maryland Baltimore

2012 **BERNARD ROIZMAN** Sc.D., Joseph Regenstein Distinguished Service Professor, University of Chicago

REN JINSHENG, Founder, Chairman, and Chief Executive Officer, Simcere Pharmaceutical Group

2011 **JONATHAN M. ROTHBERG**, Ph.D., Founder, CEO and Chairman, Ion Torrent Corporation

THOMAS WATKINS President and CEO, Human Genome Sciences Inc.

2010 **ERIC GREEN**, M.D., Ph.D., Director, National Human Genome Research Institute, National Institutes of Health

GABRIEL LEUNG, President, Pharmaceuticals Business, OSI Pharmaceuticals

2009 **LUC MONTAGNIER**, M.D., 2008 Nobel Laureate for Physiology and Medicine, Emeritus Professor, C.N.R.S. President of the World Foundation for AIDS Research and Prevention

ROBERT C. GALLO, M.D., Director and Professor, Institute of Human Virology of the University of Maryland School of Medicine

NANSHAN ZHONG, M.D., President of China Medical Society, Member of Chinese Academy of Engineering

ZHONG NAN-SHAN, M.D., 中华医学会会长, 中国工程院院士

CBA Outstanding Service Award Recipients

The CBA Outstanding Service Award was established in 2003 to honor individuals who have made significant contributions to CBA:

2017 **PING CHEN**, Ph.D., Founder and CEO of Anyu Biomed Inc.

2016 **RICHARD ZHAO**, Ph.D., Professor, University of Maryland School of Medicine

2015 **ZHIFENG LONG**, Ph.D., President, Peronsal Diagnostix

2014 **SUJUAN BA**, Ph.D., Chief Operating Officer, National Foundation for Cancer Research

2013 **YIFAN ZHAI**, M.D., Ph.D., CEO & President, Healthquest Pharma

2012 **LIN SUN-HOFFMAN**, J.D., Ph.D., President, Sun-Hoffman Consulting

2011 **YULING LI**, Ph.D., Fellow, Process Biochemistry, MedImmune

2010 **DAJUN YANG**, M.D., Ph.D., Co-Founder, Chairman & CEO, Ascentage Pharma Group Corp.

2008 **YINGXIAN XIAO**, Ph.D., Associate professor, Georgetown University School of Medicine

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA PAST PRESIDENTS & CONFERENCES



2017 **DONG SHEN** Delivering Lifesaving Medicines to Patients through Innovation, Regulatory Reform and Global Partnership

2016 **XURONG JIANG** Biopharm US-China: Accelerating Global Development and Commercialization through Partnership

2015 **SHOU-BAI CHAO** Globalization of Biopharmaceutical Development and Commercialization – Emerging Market Opportunities

2014 **ZIPING WEI** Advancement and Global Opportunities in Innovative Biopharmaceutical Development

2013 **PING CHENG** Global Partnership in Biopharmaceutics and Translational Medicine

2012 **RICHARD ZHAO** Emerging Market for Biopharmaceutics in Asia: Opportunities and Challenges

2011 **ZHIFENG LONG** From Personal Genomes to Translational Medicine

2010 **SUJUAN BA** Biopharmaceutical Medicines: Development and Commercialization without Boarders

2009 **YIFAN ZHAI** Biopharmaceutical Innovation and Commercialization

2008 **LIN SUN-HOFFMAN** Biotechnology Innovation and Sustainable Development

2007 **YULING LI** Dynamic Biopharmaceutical Development: from Discovery to Commercialization

2006 **DAN ZHANG** Dynamic Changes in the Biopharmaceutical Industry: Challenges and Opportunities

2005 **DAJUN YANG** Biopharmaceutical Globalization: Strategies and Perspectives

2004 **ROXANNE DUAN** Trends in Biotechnology: New Strategies and Perspectives

2003 **YINXIAN XIAO** Biotechnology & Pharmaceutical Industry: Technology Platforms and Business Models

2002 **JIAN NI** Drug Development in USA and China: Impact of Human Genome Project and World Trade Organization

2001 **JIAN NI** Biotechnology: From Research to Commercialization in Life Science Industry.

2000 **WEI WU** He Biotechnology: Genomics in the Information Age

1999 **SUN LU** Biotechnology, Genomics and Beyond

1998 **PATRICK LU** Biotechnology: From USA to China

1997 **PATRICK LU** Biotechnology: From Benchtop to Marketplace

1996 **GUOLIANG YU** Biotechnology: Today and Tomorrow

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA BOARD OR DIRECTORS & ORGANIZING COMMITTEE

cba-usa.org

CBA Board of Directors

George Chang
Shou-Bai Chao
Ping Chen
Steve Chen
Zhenxia Chen
Yali Fu
Xu-Rong Jiang
Feiyan Jin
Alex Lai
Shoupeng Lai
Zhifeng Long
Xiaobin Lu
Helen Mao
Jian Ni
Linda Powers
Peter Qian
Edward Wang
Ziping Wei
Jean Xiao
Yingxian Xiao
Qiao Yu
Monica Zhang
Richard Zhao
Frank Li Li
Dong Shen
Jingyu (Julia) Luan
Chuanhua (Julia) Xing
Yuling Wu
John Li
Jincheng Wu

The Organizing Committee of CBA 23rd Annual Conference

Chairman: Frank Li Li

Sujuan Ba
Shoubai Chao
Yali Fu
George Chang
Jack Che
Yan Guo
Yixing Han
Xurong Jiang
Feiyan Jin
Alex Lai
Kevin Li
Jenny Li
Yuling Li
Hang Lu
Xiaobin Lu
Patrick Lu
Julia Luan
Helen Mao
Peter Qian
Dong Shen
Lin Sun
Victoria Sun
Xiangping Wang
Jincheng Wu
Yuling Wu
Julia Xing*
Vivian Xu
Judy Yu *
Alice Zhang
Limin Zhang
Xuejuan Julie Zhang
Richard Zhao
Hang Lu
*Group Lead

ZHEJIANG HISUN PHARMACEUTICAL CO., LTD

浙江海正药业有限公司

HISUN 海正药业

Company History

1956 ---Foundation of Hisun

1998 --- Hisun Pharm Set Up

2000 --- Public Listed

2009 --- New Expansion:

Hisun USA Established

Fuyang Site Established

Animal Health Established

2012 --- Hisun-Pfizer Established

Legend to be continued…

Company Overview

Hisun is a fully integrated pharmaceutical company. We focus on providing a broad range of products and services for the benefit of all who use them. Our products are manufactured to the highest standards for the overall health and wellness of our patients. We focus our research on conditions that affect people around the world while continuing to invest in broadening our technology and product portfolio. We apply our breadth of technologies, skilled workforce, state-of-the-art facilities while leveraging a cost competitive base for the benefit or our clients and partners. Our facilities have been inspected by local and international regulatory agencies, including US FDA, EMA and many other authorities.

Humane-oriented, innovating, self-motivating, united, natural"

(HISUN)

Now We Are Recruiting…

Biomedical related

- Senior scientist
- Associate Director
- VP of biomedical research

Quality Assurance related

- Various positions

Welcome to CBA's website and our booth for more details

Please also visit our websites for more information

www.hisunpharm.com

www.hisunusa.com



亞 盛 醫 藥
Ascentage Pharma

COMPANY OVERVIEW

ASCENTAGE PHARMA is a globally-focused clinical stage biopharmaceutical company developing novel small molecule therapeutics to restore programmed cell death (apoptosis) in cancers, hepatitis B and aging-related diseases. The Company is also developing next-generation tyrosine kinase inhibitors.

HIGHLIGHTS

- 4 clinical programs targeting 3 distinct apoptotic pathways: Bcl-2/Bcl-xL, Bcl-2 selective, IAP dimer, MDM2-p53
- 7 novel candidates in Phase I/II development with First-in-class and Best-in-class potential in US, CHINA and globally
- Unique platform for designing small molecule drugs that inhibit complex protein-protein interactions (PPIs); break-through technology based on U of Michigan collaboration
- Global partnership with Unity Biotechnology for therapies to treat aging-related diseases (senolytics)
- $90 million raised to date

PIPELINE

Candidate	Mechanism	Indications	IND Enabling	Phase I	Phase II	Rights
Apoptosis Targeted Compounds (Global Markets)						
APG-1252	Bcl-2, Bcl-x_L 2nd Gen.	SCLC, Lymphoma, Solid Tumors	*Phase I dose escalation in US; Phase I SCLC in China & AUS*			Global
APG-2575	Bcl-2 Selective	B-cell Cancers	*US IND accepted; Phase I to start in 1H18*			Global
APG-1387	IAP Dimer	Cancer, HBV	*Phase Ib & combo studies in US; Phase Ib in AUS & CHN; Phase I HBV in China*			Global
APG-115	MDM2-p53	Cancer, Dry AMD	*Phase I dose expansion in US and China*			Global
Kinase Inhibitors (China Market focused)						
APG-8361	c-Met Selective	c-Met+ Cancer	*US Phase I completed; in Phase I/II in C*			Asia Pacific incl. Japen
APG-1351	Bcr-Abl Mutant 3rd Gen.	CML (T315I+), GIST	*Phase I in China*			Global
APG-2449	FAK.	NSCLC (ALK, Ros, FAK)	*CHN IND filing expected 1Q18*			Global
Collaborations – Summary Information Provided						
Unspecified	Ascentage has a WW partnership with UNITY Biotechnology to co-develop senolytic drugs					China

COMPLEMENTARY TO I-O & TARGETED THERAPIES



Multiple Indications in Cancer



Opportunities for Single-Agent and Combination Therapies

For more information, please visit www.ascentagepharma.com.

SalubrisBio

About Salubirs

Salubris Biotherapeutics, Inc. (SalubrisBio) was founded in August 2016 as a subsidiary of the China-based pharmaceutical company Salubris Pharmaceuticals Co. Ltd. (Salubris Pharmaceuticals). SalubrisBio is an innovation-focused biotech with pioneering research and development programs. Headquartered in Gaithersburg, Maryland, SalubrisBio represents and reflects Salubris Pharmaceuticals' commitment to innovation and expansion into the global market. SalubrisBio focuses exclusively on the discovery and global development of novel, biologic therapeutics.

Salubris Pharmaceuticals is a publicly-traded company [002294:CH], founded in 1998, which has grown to achieve sales of >$700M USD in 2016. Salubris Pharmaceuticals is a fully-integrated drug development company. Headquartered in Shenzhen, China, Salubris Pharmaceuticals has over 3,000 employees working across R&D, regulatory, marketing and sales. Its marketed products include small molecule drugs in the cardiovascular, anti-allergy and anti-infective therapeutic areas.

GeneKey Biotech Ltd. Co. (GeneKey Biotech), based in Chengdu, China, is the China-based biologics subsidiary of Salubris Pharmaceuticals. GeneKey Biotech has a robust portfolio of biosimilar and novel large molecule therapeutics in development in China. SalubrisBio maintains close cross-functional collaborations with GeneKey Biotech, leveraging resources including the expertise of >150 research scientists and large-scale manufacturing up to 2000L scale.

华越医疗器械供应链服务平台

Supply Chain Service Platform For Medical Devices



合众共创 聚赢未来

打造医疗器械供应链第一服务平台

使命/Mission

重构商业模式 整合协同资源 共享共生共赢

愿景/Vision

缔造医疗器械供应链新生态

Marketgene Capital

明智资本 Marketgene Capital

Discovery value , Realized value

WISE IPO

1 COMPANY INTRODUCTION

With the most of prescription and best value, it helps high-quality enterprises to link up capital markets.
Escort the high-quality enterprises “step in, pile out”.

Marketgene capital Ltd is an international enterprise , specializing in "domestic and overseas market guidance, equity investment, post-ipo price maintenance", headquartered in Hong Kong and the branches were established in UK and China; We incubated and hold stock rights of lots of high-quality companies;The main business of Market capital Ltd is the domestic and overseas capital market operation, domestic and overseas listing guidance for companies , and the price maintenance of green shoes after listing; We are good at integrating Chinese accounting standards with international financial reporting standards.We also directly invest in a number of high-quality enterprises or with the latent quality of listed companies in different areas of China.

2 MAIN BUSINESS

- Business Incubator、 Business model、Law、Accounting business
- Listing Guidance、Financial norms、IPO
- lead Investment 、Direct Investment、Introduct early investment
- Integrate with international accounting standards 、Domestic listed accounting compliance.
- To coordinate domestic and overseas financial institutions and exchanges.
- Global tax planning and design, implementation of the best tax legal scheme.
- Design and establish the internal control system of the enterprise.
- The future prediction of the listed subject.
- Before the private placement of private equity, help to issue the original private equity.
- T he price maintenance of the green shoes, the price maintenance after the listing.

3 TEAM PRESENTATION

Jonathan Chung
Director

Ph.D., Columbia University, USA;
American certified financial planner;
Hong Kong securities and futures commission
Former South African standard bank Asia Pacific President;
He was a vice President of derivatives at Merrill Lynch.

Frank Lin
Director

Doctor of finance, Wharton university, USA,
US CPA (US CPA),
PWC auditor.
Good at Chinese financial standards and international accounting standards;
UK GXG sponsor qualification.

Sophia Sun
CEO of chinese zone

CBA deputy director and Secretary General of the CBA Office
2016 outstanding new quotient merchants
Overseas asset management companies.
More than 15 years industry experience;
Good at international capital operation,
Good at enterprise listing and price maintenance.

4 SICHUAN INTERNATIONAL HAIBO BIOMEDICAL INCUBATION PARK

It aimed to be established an International Biomedical Park by a number of senior industry experts ,who are the most professional people

- **Business Incubation \Model International Law、Accounting**
- **Investment、Maintence Price after listing**
- **Listed Counselling 、Financial regulation、Global tax planning**
- **Connecting business adminstration \ Internal planning \Maintence of foreign relation**

5 CONTACT US

Hong KeeCapital Building, 135 Beach Road, Hong Kong.
OCG International Center, The Fourth Tianfu Street,High-tech Zone, Chengdu, China.
TEL:0086-69295235 0086-18628220888
EMAIl：sophiasun11@hotmail.com ; cba-sc@163.com

China Resources Life Science Park

China Resources Life Science Park (CRLSP) is an ideal place for life science companies to establish innovation, R&D, and manufacturing facilities. It covers an area of over 100 acres, an expecting constructional floor area of 1,020,000 m². As one of the key projects of CBP (China Bio-medicine Park) base.

CRLSP has leveraged national level research resources and its location right in the capital to turn itself into a world-class industry town. Within specially dedicated zone policy that enjoy a series of benefits from municipal, provincial and central governments. Companies can enjoy benefits like government-backed financing, tax breaks and grants for research and scientist. The one-stop shops are where, companies can combine suppliers, clients and the talent pool together.

By providing innovative incubator, funds and professional service from CR group, CRLSP is trying to maximize the success possibilities of incubation.

CRLSP in the core of Beijing-Tianjin-Hebei Region

18.6 miles south of Tiananmen Square
1.86 miles to subway line 4
12.4 miles to Beijing Da' xing International Airport
40.4 miles direct to Xiong' an New Area
105.6 miles away from Tian' Jin Port



China Resources Group

Established in 1938 and headquartered in Hong Kong
China SASAC A-Level
Ranked 86st place Global 500 in 2017
Owns 10 Holding Companies
With an total assets of 161.6 billion USD
With the largest healthcare group in Asia
(over 14,000 beds)
The second largest pharmaceutical group in China
(18.6 billion USD revenue in 2016)

China Resources Life Science Development Co,. Ltd
Add: 17/F, Tower H, Phoenix Place, 5A Shuguang Xili,
Chaoyang District, Beijing, P.R.C 100028
Web: www.crc.com.hk
Email: crlife@crc.com.hk

Frontier Biotech Corporate Introduction

Frontier Biotechnologies Inc ("Frontier Biotech") is a China-based global biopharmaceutical company with core competence in developing novel anti-viral and long-acting drug products. Founded in 2002, Frontier Biotech has been dedicated in the discovery, development, manufacture and commercialization of innovative drug products targeting unmet clinical needs for the past 16 years. The management team has extensive business and development experience in pharma/biotech industry in US, China and Japan. Our mission is to become a science-driven biopharmaceutical company with global competitiveness and to develop innovative therapies for addressing unmet medical needs for patients and the society. Currently the company has three drug candidates in late-stage development.

Albuvirtide (ABT) is the first novel AIDS drug in China and the second long-acting AIDS drug in the world, with a novel molecular mechanism of action. Data from a phase 3 clinical trial illustrated that Albuvirtide was safe and effective against major strains of HIV including resistant viruses. An NDA has been filed to CFDA.

3BNC117 is a fully human broad spectrum HIV neutralizing monoclonal antibody (bNAb) licensed from The Rockefeller University. It is one of the best bNAbs and the most advanced in clinical development in the world. Frontier Biotech intends to combine Albuvirtide with 3BNC117 to form an all-injectable long-acting drug regimen for viral suppression and viral reservoir clearance.

AB001 is a third generation topical patch for pain management. A proof-of-concept phase 2 trial in patients with chronic low back pain was completed in the US, and endpoints were met with statistical significance.

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

SPONSOR HIGHLIGHTS

DIAMOND

NaiLii 耐利装备
NaiLii Biotechnology Engineering

Shanghai Naili Ltd. Founded in May 2003, located in State-level Economic and Technology Development Zone of Songjiang, Shanghai. The company covered an area of 27,700 m2 and invested over 235 million RMB. There are over 160 staffs and over 55% of them are professional technicians. The company devoted itself in biopharmaceutical industrialization and process optimization, including the development, design, production and installation of the related equipment, integrating technology, equipment and engineering together.

Shanghai Naili company focuses on the construction of antibody, vaccine and generic drug industrialization project. The company provides laboratory scale, pilot scale and large-scale industrialization system equipment. The whole process engineering design of Bio-product industrialization provides one-stop turnkey service for all systems and related equipment related to industrial process, as well as engineering installation, system commissioning, function verification, single machine control and DCS system construction.

GOLD

药明康德 WuXi AppTec

WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated."

Our vision is to become the most comprehensive capability and technology platform in the global pharmaceutical and healthcare industry to fulfill the dream that "every drug can be made and every disease can be treated".

HISUNUSA

Hisun Pharmaceuticals USA, established in 2009, is an emerging pharmaceutical company committed to the development, manufacture and commercialization of pharmaceutical products for the US market place with a focus on APIs, Generics, Specialty and Animal Health Products. Hisun USA also provides contract manufacturing services through its parent company Zhejiang Hisun Pharmaceutical Co. Ltd.

Zhejiang Hisun Pharmaceutical Co. Ltd., established in 1956, is headquartered in Taizhou, China with more than 7,000 employees. Zhejiang Hisun Pharmaceutical Company is one of the largest Active Pharmaceutical Ingredient (API) manufacturers in China. Our API products are shipped to our partners throughout the world. Zhejiang Hisun Pharmaceutical also manufactures finished dosage pharmaceuticals – capsules, tablets and parenterals – for Anti-Infective, Cardiovascular, Oncology, CNS, Animal Health and other therapeutic areas. Zhejiang Hisun Pharmaceuticals also has Antibody Drug Conjugate (ADC) and biosimilar manufacturing facilities. Hisun USA is well positioned for growth in the United States, supported by our state-of-the-art facilities, manufacturing expertise, research and development capabilities.

亞盛醫藥 Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company is running 17 clinical studies in US, Australia and China.

信立泰 SALUBRIS

Shenzhen Salubris Pharmaceuticals Co., Ltd (Salubris) is a comprehensive group pharmaceutical company that integrates pharmaceutical products research and development, production and business sales, which is founded in 1998 and listed in the Small and Medium Enterprise Board of Shenzhen Stock Exchange in 2009.

Salubris is ranking top 10 in market value among Chinese pharmaceutical companies, and was named "the most competitive domestic pharmaceutical listing corporation top 20" and awarded "Top 10 Market Value Enterprises listed on SMEs Board". Salubris layouts the global industrial chain precisely and the global business has covered more than 38 countries and regions, including China, USA, Germany, France and Japan.

The company business focuses on the therapeutic fields of cardiovascular, anti-diabetic, antineoplastic and orthopedic, as well as three mainlines of the high-end chemical medicine, innovative biological medicines and medical apparatus and instruments, forming the strategic synergy between products. In the cardiovascular field, the key products are all either innovative or the first launcher to the market. This has established a leading position in the industry.

华越供应链平台 HuaYue MDD

The Jiangsu Huayue Medical Device Investment Corporation Ltd is also known as the China Med Pharma Park Medical Device Public Service Platform. Established in the China Med Pharma Park, it serves as a comprehensive service platform for medical device companies. It covers a total area of 20,000 m2, and has spacious warehouse, complete cold chain facilities, GMP- compliant software, professional operation and management teams, and service centers for one-stop application and registration for medical devices. It provides third-party storage and transportation services to medical device manufacturers and distributors.

When you open and operate your medical device companies at Huayue, you will have access to our supporting facilities such as office space, warehouse, cold chain, and transportation, which will make your application and registration process more efficient, less labor intensive, and more cost effective. You will enjoy the shared cold chain facilities, shared warehousing, and speedy processing.

Over 300 medical device companies have landed on our platform. The highly integrated information system of our platform allows companies to have remote data exchange using the 3PL system and the platform's WMS system. You can obtain automatically generated, fully traceable records of purchasing, sales, warehousing, and transportation with the click of a button. By using our platform, you can be assured that your process is efficient and in compliance, which will save you a lot of trouble in the future.

cba-usa.org

SPONSOR HIGHLIGHTS

SILVER

明智资本 Marketgene Capital

Marketgene capital Ltd is an international enterprise , specializing in "domestic and overseas market guidance, equity investment, post-ipo price maintenance", headquartered in Hong Kong and the branches were established in UK and China; We incubated and hold stock rights of lots of high-quality companies;The main business of Market capital Ltd is the domestic and overseas capital market operation, domestic and overseas listing guidance for companies , and the price maintenance of green shoes after listing; We are good at integrating Chinese accounting standards with international financial reporting standards. We also directly invest in a number of high-quality enterprises or with the latent quality of listed companies in different areas of China.

Celetrix Electroporation

Celetrix was founded in 2012 in Virginia to commercialize new tyes of high effiiciency electroporators .The company has a team of accomplished biomedical scientists that also understand the properties of complex cell-to-cell electrical interactions. As a result, Celetrix has revamp the traditional procedures of cell electroporation with the introduction of innovative electroporation devices and methods.

Celetrix is a proud participant of the NIH SBIR/STTR grant program. Besides the electroporation products, Celetrix is also dedicated to providing development services to biotech companies and research institutions.

At Celetrix, highest product and service quality is our pledge. Together,we can achieve impossible goals in the thriving biomedical community.

华润医药商业 CR Pharmaceutical Commercial

China Resources (Holdings) Co., Ltd. ("CR" or "China Resources Group") is a diversified holding company registered in Hong Kong. CR was first established as "Liow & Co." in Hong Kong in 1938, In 2003, under the direct supervision of SASAC, it became one of the key state-owned enterprises.

Under China Resources Group there are seven key strategic business units, 17 grade-1 profit centers, 1,987 business entities, and more than 420,000 employees. On October 28, 2016, China Resources Pharmaceutical Group Limited (3320HK) was officially listed on the Hong Kong Stock Exchange. China Resources Group is one of the Fortune Global 500 enterprises, ranking 86 in 2017. CR's retail business, Snow beer brand and gas operations are the largest of their kind in China. CR Power and CR Cement have industry-leading business performance and operational efficiency. CR Land is one of the most reputable and integrated real estate developers in mainland China. CR Pharmaceuticals' sales volume is among the best in China, while "Snow" beer, "C'estbon" purified water, "CR Vanguard" supermarkets, and the "MIXC" mall, 999, CR Double-Crane, Dong-E-E-Jiao are all household brands in China.

Since the advent of the 21th century, CR has built a strong industrial foundation, and significantly increased its overall competitive strength.

PharmEng Technology

PharmEng Technology has been providing quality services to the manufacturers of health care products for over 15 years. In highly regulated industries, there is a need for experienced specialists who can provide solutions in a cost effective and timely manner. PharmEng Technology is a full service consulting firm that specializes in Commissioning & Qualification, Validation, Quality Systems, Regulatory Affairs, Engineering and Training. We provide a wide range of services to the pharmaceutical, biotechnology, medical device and nutraceutical industry. We are a global company and we are here to assist your company with any issue you may be facing.

At PharmEng Technology, we have a highly qualified and dedicated professional team who believes quality plays an integral role in every facet of our activities. Our international presence ensures we are current with regulatory practices and ahead of the emerging trends around the globe. Our staff brings a variety of disciplines to the table, to ensure every aspect of your project needs are met. PharmEng Technology is a multicultural company with staff all over the world servicing companies of all sizes. We are confident that we are the solution you need to operate in this highly regulated industry.

Waters
THE SCIENCE OF WHAT'S POSSIBLE.™

Waters Corp., a publicly traded corporation (NYSE:WAT) headquartered in Milford, Massachusetts, holds worldwide leading positions in complementary analytical technologies - liquid chromatography, mass spectrometry, rheometry and microcalorimetry. These markets account for approximately $5.0 billion of the estimated $20 - $25 billion worldwide analytical instrumentation market.

Specifically, the company designs, manufactures, sells and services ultra performance liquid chromatography (UPLC), high performance liquid chromatography (HPLC), chromatography columns and chemistry products, mass spectrometry (MS) systems, thermal analysis and rheometry instruments.
Waters Corp. operates in two divisions: Waters Division and TA Instruments.

上海辅仁医药研发 SHANGHAI FUREN MEDICINE R&D

Established in August 2015, Shanghai Furen Medicine R&D Co., Ltd. is a leading research and development center for new therapeutics and new medical technologies. The parent company of Shanghai Furen, Furen Medicines Group, is one of the top 50 pharmaceutical companies in China.

Shanghai Furen has two campuses. Its Minhang Campus, which has 18,000 square meter (193,000 square feet) of offices and research laboratories, is located in DP-PARK, Lingang Pujiang International Science and Technology City. In addition, Shanghai Furen is building its Songjiang Campus, which will have 42,000 square meter (452,000 square feet) of offices and laboratories.

Shanghai Furen is establishing five R&D platforms: Cell Therapies, New Therapeutics (large molecules), New Therapeutics (small molecules), Generics and Other Health Products. As the strategic focus of Furen Medicines Group, Shanghai Furen has undertaken the important missions of promoting technology and management innovations, and opening up new growth paths. Shanghai Furen is using Shanghai's unique advantage in geography, talent, economy, transportation and innovative environment to build a world-class innovation center.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

SPONSOR HIGHLIGHTS

CrownBio
CONNECTING SCIENCE TO PATIENTS

Crown Bioscience Inc. is a cutting edge translational technology company providing drug discovery and clinical development services in the areas of oncology, inflammation, cardiovascular, and metabolic disease.

CrownBio brings clarity to drug discovery and enables clients around the world to deliver superior clinical candidates. Our premier Translational Platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs. We develop world-leading preclinical efficacy models and provide both in vitro and in vivo testing services as well as preclinical research products.

CrownBio also provides preclinical immunotherapy research platforms to support the successful transition of immunotherapeutics from the lab into the clinic including models f or the evaluation of CAR-T therapies, syngeneics, and humanized models.

Frontier 前沿生物

Frontier Biotechnologies Inc ("Frontier Biotech") is a China-based global biopharmaceutical company with core competence in developing novel anti-viral and long-acting drug products. Founded in 2002, Frontier Biotech has been dedicated in the discovery, development, manufacture and commercialization of innovative drug products targeting unmet clinical needs for the past 16 years. Our mission is to become a science-driven biopharmaceutical company with global competitiveness and to develop innovative therapies for addressing unmet medical needs for patients and the society. Currently the company has three drug candidates in late-stage development.

Albuvirtide (ABT) is the first novel AIDS drug in China and the second long-acting AIDS drug in the world, with a novel molecular mechanism of action. An NDA has been filed to CFDA.

3BNC117 is a fully human broad spectrum HIV neutralizing monoclonal antibody (bNAb) licensed from The Rockefeller University. It is one of the best bNAbs and the most advanced in clinical development in the world.

AB001 is a third generation topical patch for pain management. A proof-of-concept phase 2 trial in patients with chronic low back pain was completed in the US, and endpoints were met with statistical significance.

sirnaomics
Advancing RNAi Therapeutics

Sirnaomics, Inc. is the only company having Innovative Platform for Novel siRNA Therapeutic Clinical Studies focus on the unmet needs including Fibrosis, Cancer & Viral Infection in both USA and China. Patrick Lu, serves as a "1000 Talents" expert and the PI of "12-5" Key Programs for innovative pharmaceuticals in China founded this company with his experienced team. Sirnaomics STP705 is entering clinical Phase IIa in USA and approved for clinical study as the 1st ever ONT drug in China.

Big Market Unmet Needs
- Focus Unmet Clinic Needs: Fibrosis, Cancer, V.Infection;
- Utilized Government Grants and Partnership Funding;
- Combined R&D Strengths from both USA and China;
- Stepwise: Topical, to Local, then Systemic Indications.

Solid Foundation in Research & Clinical Stage
- Strong IP Portfolio: 25+ Patents, 10 PCTs, 8 Issued
- Highly Effective Multi-Target siRNA Drug selection with High Specificity & Low Toxicity;
- Inhibit Production, Eliminate the Root Causes of Disease;
- Unique Polymer Nano-Particle (PNP) Delivery System;
- Rich Product Pipeline: all "first-in-class".

National Foundation for Cancer Research
Research for a Cure

The National Foundation for Cancer Research (NFCR) is a 501(c)(3) nonprofit organization that provides scientists in the lab the funding they need to make game-changing discoveries in cancer treatments, detection, prevention and, ultimately, a cure. The organization has distinguished itself in the cancer research sector by emphasizing long-term, transformative laboratory initiatives often overlooked by other major funding sources. Too, NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. With the help of more than 5.2 million individual donors over the last 45 years, NFCR has delivered more than $360 million in funding to public education and cancer research leading to several important, life-saving discoveries.

Our work would not be possible without the support of millions of individual donors across the United States and around the world. With continued support, we will continue to foster collaboration amongst scientists around the world and across disciplines; provide seed funding and flexibility for innovative ideas and research; and maintain our long-term vision and commitment to cancer research.

We envision a future without the specter of cancer, and we will not stop until we find a cure for all types of the disease.

华海药业 HUAHAI PHARMACEUTICAL

Zhejiang Huahai Pharmaceutical Co., Ltd was founded in 1989 and headquartered in Zhejiang, China. It is a listed pharmaceutical company, specializing in research & development, manufacturing and sales of APIs, formulations, biological and new drugs. Huahai, with over 6,500 employees worldwide, has over 30 subsidiaries located in USA, Japan, Russia, Spain, India, etc.

First Chinese pharmaceutical company approved by both US and EU authorities for cGMP manufacturing of formulation.
First Chinese pharmaceutical company approved by both US and EU authorities for ANDA licenses.

eurofins | Pharma Discovery Services

Eurofins Pharma Discovery Services has been supporting Drug Discovery research for over 40 years. Through the combined expertise of Eurofins Discovery Services, Cerep, DiscoverX, Panlabs, and Villapharma we offer a broad portfolio of products and services including; in vitro pharmacology, cell-based phenotypic assays, chemistry services, ADME-Tox, in vivo drug safety and efficacy, custom proteins, and assay development services.

Maryland
OPEN FOR BUSINESS

Welcome to Maryland. Maryland is in the prime commercial corridor between New York and Washington, D.C. The state has a world-class multi-modal transportation infrastructure; 350 federal, academic and private research labs; and a diverse, highly skilled workforce. Maryland has the highest concentration of Ph.D. scientists and engineers in the United States. A leader in vaccine development and adult stem cell production, Maryland is home to one of the largest life sciences clusters in the country. The state's rapidly growing bio-ecosystem includes biopharma, genomics, medical devices, nutraceuticals, personalized and regenerative medicine, and more. The Maryland Department of Commerce can help you establish your business here. Our team members include industry specialists and we have an office in China. We can provide information on the local and national environment, help identify investment opportunities, make introductions to potential partners, arrange site visits and meetings, and support workforce training needs.

cba-usa.org

SPONSOR HIGHLIGHTS

BRONZE

ORIGENE

OriGene Technologies, Inc. is a go-to resource for researchers in gene function studies. Founded in 1996, headquartered in Rockville, MD, OriGene has branches in China and Germany. OriGene supplies gene-centric tools for human/mouse/rat, including

1. cDNA expression plasmids/Lenti vectors
2. Recombinant Proteins
3. Antibodies and Assays
4. CRISPR vectors/Knockout/Knock-in kits

For more information, visit www.origene.com.

Promega

Promega's solutions span the lab workflow from drug discovery with biologics and small molecule to a portfolio of easy to use assays and protocols for a comprehensive assessment of cell health state. No matter what your lab is working on Promega has the tools for you to be successful in your research. Stop by our table while at the CBA Annual Conference to learn more about how we can work with you.

Adagene 天演药业

Adagene (Suzhou China) is an innovative antibody engineering and discovery company for global unmet medical needs. Utilizing its proprietary Dynamic Precision Library Platform (DPL), Adagene is developing immuno-oncology antibodies against novel epitopes that give unique product profiles that have potential to succeed where other groups have failed.

Adagene is showcasing its exceptional antibody engineering capabilities by building franchises of products with multi-specific antibodies that are cross-species reactive to accurately find the correct structural relationship and drug combinations to find the ideal therapeutic. Also, Adagene is developing a third-generation technology, SAFEbody™ to enhance the therapeutic window for antibodies.

Adagene's lead product is filing INDs in the US, Australia and China in mid-2018 which exhibits robust single agent and combination activity in multiple pre-clinical models. Also, Adagene's second and third products are currently anticipated filing global INDs in 2019 and 2020.

The company's management team is composed of industry veterans with proven track record in therapeutic antibody R&D. Adagene is backed by top notch global venture funds such as F-Prime Capital Partners, Eight Roads Ventures, 6 Dimensions Capital, GP Healthcare Capital, New World TMT Ltd and Sequoia China. The company has raised over $85 million through its series A to C financing.

BI ,i. BRAND INSTITUTE

Where Great Brands Begin!®

Founded in 1993, Brand Institute (BI) was created on this principle: provide the highest quality name development services, produced and presented by the most experienced professionals, in a timely manner, and at a competitive price. As we strive to deliver industry-leading nomenclature services, we are constantly adapting to our clients' needs to deliver greater value and successful outcomes.

We recognized early on that we are only as good as our people. We purposefully brought on and retained in-house healthcare and branding professionals to offer the best value, knowledge, experience and service to our clients. We understood the highly specialized nature of our business and tailored our methodology to be more specific to our healthcare, consumer and B2B clients' needs. We listened to our clients and we learned from regulatory and industry leaders, quickly evolving to changes in the marketplace. We kept a laser focus on our core competencies (Brand Strategy, Name Creation, Trademark Screening, Market Research, Safety Research, Regulatory Affairs, and Design) and continuously innovated in each of these areas.

These principles and the dedication of our people have allowed Brand Institute to become the world's leading branding consultancy with a portfolio of more consumer & healthcare brand names and identities than any other company in the world (over 3,000 brands for 1,000+ companies)!

BioLegend®

BioLegend develops highly recognized, world-class antibodies, recombinant proteins, and reagents manufactured at our facilities in San Diego. Our mission is to accelerate research and discovery by providing the highest quality products at an outstanding value, along with superior customer service and technical support. Our product portfolio includes tools for research in immunology, neuroscience, cell biology, cancer, and stem cells. We have developed over 18,000 products, collectively cited in over 27,000 peer-reviewed journal publications. With our addition of the former Covance antibody team of experienced neuroscientists, its portfolio and Massachusetts facility, BioLegend enables discovery in Neurodegeneration, Neuroinflammation, and Synaptic Biology research. Our Cell Biology products cover areas including cellular metabolism, structure, signaling, epigenetics, and cell cycle. BioLegend in San Diego, CA is now operating under an ISO 13485:2003 certified quality management system.

成都医学城 CHENGDU MEDICAL CITY

Chengdu, the provincial capital of Sichuan Province in China.Totally, 16 countries have set up respective consulates at Chengdu. 331 enterprises among the Fortune Global 500 enterprises have set up their offices in Chengdu.The Chengdu Medical City is located at the Wenjiang District which is the vital part of Chengdu. It focuses on developing three industries, including medical science, medical treatment, and medicines. It has successfully established three industry bases, such as I-Bridge Capital, Cybernaut and TCL, with raised funds of RMB 1.6 billion. The Chengdu Medical City "Three-Medical Innovation Center" Project (Phase III) is the Phase I Project set up in scientific innovative base of Chengdu Medical City. Such project was invested and constructed by Chengdu GeUnion Kehai Health Technology Co., Ltd. which is a state-owned enterprise at Wenjiang District. Such project features an overall investment of RMB 1.295 billion, an area of 111.66 mu, and an overall planned building area of 195,558 m2. It will have been completed for use by June of 2018. Such project intends to construct the innovation and industrial promotion platforms serving for "three-medical integration", including five platforms such as technology, information, talents, finance, government affairs and incubation services, and create a high-end bio-pharmaceutical professional ecological park integrating technical research and development, pilot production, industrialization service, living as well as comprehensive set.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

SPONSOR HIGHLIGHTS



Sino Biological

Sino Biological Inc. is a world leading biological reagents manufacturer, offering premium quality reagents, Proteins (6000+), Antibodies (9000+), Genes (20000+) and ELISA Kits, all of which are produced in-house and cover a broad range of life science research and drug development. It also provides one-stop services for protein and antibody discovery, research, development, production and commercialization.

ATCG 阿思科力

ATCG was found in December 2013 at Biobay, Suzhou-Singapore Industrial Park, Suzhou, China, by Dr. Huashun Li who is a prestigious scientist with over 30 years working experience in biomedical science both in the US and China. ATCG has been focused on developing innovative "off-the-shelf" CAR-NK cell drugs for cancer immunotherapy. The R&D team at ATCG, led by Drs. Huashun Li, Qihong Sun and Yi Wei, has been based on natural killer cell line NK-92 as a platform to develop over 15 CAR stably expressing NK cell lines (CAR-NK) to treat different types of solid tumors. The preliminary clinical research studies have shown that ATCG427 CAR-NK therapy yields a remarkable response rate and partly persistent remission in the treatment of over 80% solid tumors including but not limited to breast cancer, lung cancer, renal cancer, and pancreatic cancer. ATCG has been well positioned in the fast growing tumor immunotherapy field with the proprietary CAR-NK technology.

天境生物 I-MAB BIOPHARMA

I-Mab Biopharma was formed by a 2017 merger between Third Venture Biotech (founded by Dr. Jingwu Zang, Tigermed and Bioscikin) and Tasgen Bio (founded by I-Bridge Capital, Tasly Shanghai and Genexine Inc.) in Shanghai, China. With the most innovative biologics R&D platform in China, I-Mab is positioned as a global player to develop the First-in-Class and Best-in-Class biologics in the areas of immuno-oncology and immuno-inflammation. I-Mab has adopted the dual-drive model of "Licensed-in advanced stage China Portfolio + In-house developed Global Portfolio", and hence established a well-structured and risk-balanced pipeline. There are currently 16 projects under development, which includes potential First-in-China blockbuster drugs licensed-in from notable international pharmaceutical companies and global Best-in-Class & First-in-Class drugs developed independently. As of end of 2017, I-Mab has already launched a global phase II MRCT, and expected to initiate 1 phase III study, 3 phase II studies, 1 phase I study as well as 2 US IND filing drugs within the pipeline in 2018. Considering the quantity, quality and progress of its pipeline, I-Mab is now among one of the top innovative biopharmaceutical companies in China.

PACBIO®

Pacific Biosciences (PacBio) is the leader in long-read, high-resolution sequencing. In an effort to overcome inherent challenges in the field of genomics, we sought to develop novel technology that pushed the boundaries of sequencing. Our Single Molecule, Real-Time (SMRT®) Sequencing Systems detect the full size-range of human genetic variation, through continuous long-reads with high consensus accuracy and uniform coverage. Average read lengths of >10kb reveal previously hidden structural variants and Indels – providing the highest resolution of human genetic variation. Our market-leading, long-read sequencing technology continues to reveal new insights in genomics that cannot be reliably detected using other sequencing methods, as evidenced by the more than 3,200 scientific publications featuring SMRT Sequencing. With a focus on the future and an experienced, passionate team, we are motivated to continue to redefine what is possible in genomics.

VitaScientific

VitaScientific is a vibrant supply company serving the life science research community. Through its extensive web portals: VitaScientific.com and CubeBiosystems.com (a brand of VitaScientific), VitaScientific puts myriad life science research tools, supplies and useful resources at your fingertips. Our mission is to bring the best research tools and supplies to all biomedical research laboratories. We strive to host a user-friendly and easy-to-navigate website where you may find reagents, assay kits, and other laboratory supplies from some of today's most innovative biomedical research companies. Our technical support team is committed to helping our customers select the right tools for their research, providing excellent customer care, and delivering superior technical support in order to ensure our customers' success.

CubeBiosystems, a brand of VitaScientific, features advanced and unique HIV research related bio reagents and more than 5000 ELISA Kits.

ANDARIX™

Andarix Pharmaceuticals is developing and commercializing novel cancer therapies that are targeted to the patients most likely to respond. Our clinical stage products target specific cancers at the molecular level, and our companion diagnostics identify the patients with the corresponding molecular signature who are the best candidates for therapy. Our products are based on our proprietary peptide targeted radionuclide technology which can image and subsequently kill cancer cells with directed radiotherapy. Three clinical trials with Tozaride (Re188-P2045) have been completed and Phase 2 studies are being planned. Our team, with more than 75 years combined experience, is committed to creating treatments that produce significant and improved outcomes for cancer patients.

科伦药业 KELUN PHARMACEUTICAL

Kelun Group a 2015 Fortune 500 company in China, with 30000 staffs in 90+ subsidiaries, offers over 520 products and is the market leader of injectable and infusion technologies. Kelun Group's revenues in 2015 exceeded RMB 39 billion, or USD 6 billion. Kelun Pharmaceutical is committed to R&D for small-molecule NCEs and biological NBEs, biosimilars, generic drugs, and new drug delivery systems (NDDS) in oncology, diabetes, hepatitis, cardiovascular and other major disease areas.
Kelun Pharmaceutical Research Institute, headquartered in Sichuan Chengdu, with the subsidiary pharmaceutical research institutes at Tianjin, Suzhou and the Kelun US Pharmaceutical Research Institute that manages Kelun US operation and Klus Pharma, has more than 990 people. Thomson Reuters in 2014 ranked Kelun the 4th most competitive pharm product pipeline in China.

cba-usa.org

SPONSOR HIGHLIGHTS

广州市生物产业联盟
GUANGZHOU BIOTECH INDUSTRY ORGANIZATION

Guangzhou Biotech Industry Organization is an alliance supervised and supported by the Guangzhou government, together with the lead of joint Guangzhou bio-tech enterprises, and founded in 2017 after the authorization by Bureau of City Affairs of Guangzhou Municipality. The Organization now owes more than 120 memberships, including bio-pharmaceutical enterprises, colleges and research institutions, medical institutions, investment organizations and other associations.

The organization is giving full use of available facilities and advantages, following the purpose of 'Combining leading enterprise, assembling quality enterprise, introducing supportive funding, accelerating clinical alternation, sharing the opportunities and improving the development of the industry'. Meantime, talent group will be formed by the expertise academicians from domestic and international-wide in the organization, which follows the path of innovative combination for both industry capital and fund capital, and be committed to build an efficient platform of rapid development and improvement for Guangzhou bio-tech companies. Also it will concentrate on the enquiries of the industry development, with proper guidance and support from government, increasing social inclusion and capitalized operation to promote the connection and integration of market resources, which finally lead to a completed loop of collaborative development, and take the lead of Guangzhou bio-tech industry.

创新，创业，创机遇，迎接全球生物制药新时代

Bridging Innovations, Entrepreneurs & Opportunities to Advance Global Biopharmaceuticals Development

CBA 2018 FULL CONFERENCE AGENDA AT-A-GLANCE



7:30-8:30
Registration and Continental Breakfast; Exhibition Booth Setup

8:30-8:35
Welcome to CBA's 23rd Annual Conference

8:35-8:50
Opening Remarks

8:50-8:55
Introduction of CBA Brilliant Achievement Awardee: Lieping Chen, M.D., Ph.D.

8:55-9:20
CBA Brilliant Achievement Award Presentation Immunological Principles of Anti-PD-1/PD-L1 Cancer Therapy

9:20-9:25
Introduction of CBA Brilliant Achievement Awardee: Richard Pazdur, MD

9:25-9:50
CBA Brilliant Achievement Award Presentation 1971-2018: Personal Reflections on Nixon's War on Cancer

9:50-10:00
Coffee Break

10:00-10:05
Introduction of CBA Brilliant Achievement Awardee: Yougjun Liu, M.D., Ph.D.

10:05-10:30
CBA Brilliant Achievement Award Presentation Follow the Science and Capture the Opportunity

10:30-10:35
Introduction of CBA Brilliant Achievement Awardee: Laurence J.N. Cooper, M.D., Ph.D.

10:35-11:00
CBA Brilliant Achievement Award Presentation: The Genetic Engineering of T cells: From Bench, to Bedside, to Boardroom

11:00-11:15
Panel Discussion

11:15-11:35
Special Presentation by WuXi AppTec: Creating An Pharmaceutical Innovation Ecosystem

Global Drug Development: ICH and Role of China

11:35-12:00
Issues in Multiregional Clinical Trials

12:00-12:25
CNDA's Regulatory Reform: Opportunities and Challenges

12:25-12:35
Panel Discussion

12:35-1:30
Lunch

1:30-2:30 PARALLEL SESSIONS A
Entrepreneur Incubators and Collaboration - Auditorium

1:30-1:45
Incubators in Montgomery County, MD

1:45-2:05
Incubators in China

2:05-2:15
Maryland Resources for Business Growth

2:15-2:25
Introduction of Maryland International Incubator

2:25-2:30
Panel Discussion

2:30-3:30
Artificial Intelligence and Big Data in Biopharmaceutical Development - Auditorium

2:30-2:50
Application of Deep Learning in Drug Discovery

2:50-3:10
Burn the Haystack: Finding the Needle in Clinical Notes & Genomics at Scale

3:10-3:30
Deep Learning Convolutional Neural Networks Techniques & Their Applications in Biomedical Sciences - A Successful Example in Lung Imaging

1:30-2:30 PARALLEL SESSIONS B
Advanced Translational Medicine - SCBA - Multi-Purpose Room

1:30-1:50
CAR-T Cells Targeting Glypicans in Cancer

1:50-2:10
Gut Microbiome Controls Liver Tumor Growth via Bile Acid-Regulated NKT Cells

2:10-2:30
T Regulatory Cells for Immunotherapy to Autoimmunity & Cancer

2:30-3:30
Real World Evidence Medicine in Biopharmaceutical Development - Multi-Purpose Room

2:30-2:50
Information Exchange and Data Transformation (INFORMED)

2:50-3:10
Realizing the Potential of Real World Data and Evidence

3:10-3:30
Panel Discussion
Panelist

3:30-3:40
Break

3:40-5:00
Entrepreneurs and Investors

3:40-3:50
Proprietary Technologies to Produce the Next Generation Growth Factors in Green Algae

3:50-4:00
Immunotherapy for Solid Tumors by Chimeric Antigen Receptor (CAR)-Modified Allogeneic Natural Killer (NK) Cells

4:00-4:10
Revamping Electroporation for Fast Manufacturing of CAR-T Cells

4:10-4:20
Stimulation of Gamma Delta T Cells for Treatment of Epithelial Solid Tumors

4:20-4:30
Targeted and Personalized Peptide Therapy - 188 Re P2045 to Treat Lung Cancer

4:30-4:40
Building a China Biopharma with Distinguished Team Pipeline and Portfolios

4:40-5:00
Panel Discussion

5:00-6:30
CEO Roundtable

6:30-7:15
Reception

7:15-8:45
Dinner Banquet

7:15-7:25
Opening Remarks by MC

7:25-8:40
NIH-CSSA Prize Drawings, Speech, Entertainment, Performance

7:25-8:40
Concluding Remarks

9:00
Conference / Event Concludes


NaiLii 耐利装备
NaiLii Biotechnology Engineering


AstraZeneca


MedImmune
A member of the AstraZeneca Group


药明康德
WuXi AppTec


HISUNUSA


亚盛醫藥
Ascentage Pharma


信立泰
SALUBRIS


华越供应链平台
HuaYue MDD


明智资本
Marketgene Capital


Celetrix
Electroporation


华润医药商业
CR Pharmaceutical Commercial


PharmEng
Technology


Waters
THE SCIENCE OF WHAT'S POSSIBLE.™


上海辅仁医药研发
SHANGHAI FUREN MEDICINE R&D


CrownBio
CONNECTING SCIENCE TO PATIENTS


Frontier
前沿生物


sirnaomics
Advancing RNAi Therapeutics


NATIONAL FOUNDATION FOR CANCER RESEARCH
Research for a Cure


华海药业
HUAHAI PHARMACEUTICAL


Promega


MARYLAND
Department of Business & Economic Development


ORIGENE


eurofins
Pharma
Discovery Services


Sino Biological
Biological Solution Specialist


VitaScientific


天境生物
I-MAB BIOPHARMA


Applied StemCell
Genome editing in vitro and in vivo


ATCG
阿思科力


BioLegend®


Johnson&Johnson


BI
BRAND INSTITUTE
Where Great Brands Begin!


成都医学城
CHENGDU MEDICAL CITY


SCPA


ANDARIX
Targeted Therapies for Personalized Medicine


CBA
Chinese Bioscience Association


PACBIO®


科伦药业
KELUN PHARMACEUTICAL


广州市生物产业联盟
GUANGZHOU BIOTECH INDUSTRY ORGANIZATION


Adagene
天演药业


AMAREX
CLINICAL RESEARCH

VIELABIO